<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11360071</article-id><article-id pub-id-type="pmcid-ver">PMC11360071.1</article-id><article-id pub-id-type="pmcaid">11360071</article-id><article-id pub-id-type="pmcaiid">11360071</article-id><article-id pub-id-type="pmid">39204389</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics16081044</article-id><article-id pub-id-type="publisher-id">pharmaceutics-16-01044</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetic Simulation and Area under the Curve Estimation of Drugs Subject to Enterohepatic Circulation</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2033-481X</contrib-id><name name-style="western"><surname>Alp&#237;zar</surname><given-names initials="M">Melchor</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="c1-pharmaceutics-16-01044" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Jes&#250;s Res&#233;ndiz</surname><given-names initials="J">Jos&#233;</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garc&#237;a Mart&#237;nez</surname><given-names initials="E">Elisa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6625-7587</contrib-id><name name-style="western"><surname>Dwivedi</surname><given-names initials="S">Sanyog</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7507-1722</contrib-id><name name-style="western"><surname>Trejo</surname><given-names initials="MA">Miguel Alejandro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="c1-pharmaceutics-16-01044" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Song</surname><given-names initials="IS">Im-Sook</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-16-01044">Specialized Centre for Diabetes, Obesity and Prevention of Cardiovascular Diseases (CEDOPEC) &amp; Bioequivalence Studies (E-BIOS-CEDOPEC), Mexico City 11650, Mexico; <email>jresendiz@cedopec.com</email> (J.d.J.R.); <email>egarcia@cedopec.com</email> (E.G.M.); <email>sanyogdwivedi@outlook.com</email> (S.D.)</aff><author-notes><corresp id="c1-pharmaceutics-16-01044"><label>*</label>Correspondence: <email>malpizar@cedopec.com</email> (M.A.); <email>alex.pharmath@gmail.com</email> (M.A.T.); Tel.: +52-5-552-825400 (M.A.)</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>16</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">469566</issue-id><elocation-id>1044</elocation-id><history><date date-type="received"><day>06</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>29</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-02 08:25:24.830"><day>02</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-16-01044.pdf"/><abstract><p>Enterohepatic circulation (EHC) is a complex process where drugs undergo secretion and reabsorption from the intestinal lumen multiple times, resulting in pharmacokinetic profiles with multiple peaks. The impact of EHC on area under the curve (AUC) has been a topic of extensive debate, questioning the suitability of conventional AUC estimation methods. Moreover, a universal model for accurately estimating AUC in EHC scenarios is lacking. To address this gap, we conducted a simulation study evaluating five empirical models under various sampling strategies to assess their performance in AUC estimation. Our results identify the most suitable model for EHC scenarios and underscore the critical role of meal-based sampling strategies in accurate AUC estimation. Additionally, we demonstrate that while the trapezoidal method performs comparably to other models with a large number of samples, alternative models are essential when sample numbers are limited. These findings not only illuminate how EHC influences AUC but also pave the way for the application of empirical models in real-world drug studies.</p></abstract><kwd-group><kwd>enterohepatic circulation (EHC)</kwd><kwd>pharmacokinetics</kwd><kwd>mathematical modeling</kwd><kwd>therapeutic drug monitoring (TDM)</kwd><kwd>area under the curve (AUC)</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-16-01044"><title>1. Introduction</title><p>Enterohepatic circulation (EHC) represents a dynamic kinetic process integral to the pharmacokinetics of certain drugs, delineating a crucial pathway within the body&#8217;s metabolic landscape [<xref rid="B1-pharmaceutics-16-01044" ref-type="bibr">1</xref>]. This intricate cycle commences with drug absorption from the intestine, where a portion of the dissolved drug traverses through the portal system to reach the hepatic lobules. Here, within the intricate architecture of the liver, the drug navigates through branches of the hepatic artery and portal vein, eventually circulating to the central vein. Along this journey, a fraction of the drug diffuses through the sinusoidal walls, finding its way into hepatocytes [<xref rid="B2-pharmaceutics-16-01044" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-16-01044" ref-type="bibr">3</xref>]. Once within these hepatic cells, the drug may undergo active transportation, facilitated by an array of pumps, such as BCRP, MATE1, MDR3, or MRP2, towards the bile canaliculi, ultimately contributing to bile formation [<xref rid="B2-pharmaceutics-16-01044" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-16-01044" ref-type="bibr">3</xref>]. Subsequently, bile, laden with the drug, travels through the bile ducts to the gallbladder, where it awaits the signal for release prompted by food intake and the hormone cholecystokinin [<xref rid="B4-pharmaceutics-16-01044" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-16-01044" ref-type="bibr">5</xref>]. The gallbladder then empties its contents, a process spanning approximately 60 min, through the sphincter of Oddi into the duodenum [<xref rid="B6-pharmaceutics-16-01044" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-16-01044" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-16-01044" ref-type="bibr">8</xref>]. Within the duodenum, the drug dissolved in bile may undergo reabsorption, initiating a new cycle of circulation. <xref rid="pharmaceutics-16-01044-f001" ref-type="fig">Figure 1</xref>a elucidates these intricate processes alongside parallel kinetic phenomena.</p><p>In studying EHC, researchers analyze time versus plasma drug concentration curves to uncover the dynamic interplay between absorption, distribution, metabolism, and excretion, revealing peaks and troughs corresponding to distinct phases of the enterohepatic cycle. Despite offering valuable insights, such analysis is challenged by variability in physiology, drug properties, and environmental factors, along with practical considerations like sampling frequency and timing. Understanding EHC is crucial in drug studies, as it profoundly influences pharmacokinetic parameters essential for determining pharmaceutical efficacy and safety. Consequently, accurately characterizing these plasma profile fluctuations poses a significant challenge in EHC studies, necessitating the development of precise models.</p><p>The journey to model EHC began with compartmental models [<xref rid="B9-pharmaceutics-16-01044" ref-type="bibr">9</xref>], conceptualizing the intestine and organism as discrete compartments with drug transfer occurring continuously [<xref rid="B10-pharmaceutics-16-01044" ref-type="bibr">10</xref>] or discontinuously [<xref rid="B11-pharmaceutics-16-01044" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceutics-16-01044" ref-type="bibr">12</xref>]. Over time, these models evolved in complexity, incorporating additional compartments to account for the gallbladder. Dynamics governing the release of bile into the intestine were then modeled with various kinetics, including continuous [<xref rid="B13-pharmaceutics-16-01044" ref-type="bibr">13</xref>], single [<xref rid="B14-pharmaceutics-16-01044" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-16-01044" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-16-01044" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-16-01044" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-16-01044" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-16-01044" ref-type="bibr">19</xref>], or multiple, the latter encompassing models utilizing switch-type [<xref rid="B20-pharmaceutics-16-01044" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-16-01044" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-16-01044" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-16-01044" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-16-01044" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-16-01044" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-16-01044" ref-type="bibr">26</xref>], sigmoid [<xref rid="B27-pharmaceutics-16-01044" ref-type="bibr">27</xref>], or sinusoidal [<xref rid="B28-pharmaceutics-16-01044" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-16-01044" ref-type="bibr">29</xref>] functions. This evolution facilitated a deeper comprehension of EHC and its ramifications on drug pharmacokinetics.</p><p>Physiologically based pharmacokinetic models represent the pinnacle of complexity within EHC modeling, treating organs and tissues as distinct entities with specific properties for both organism and drug [<xref rid="B30-pharmaceutics-16-01044" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-16-01044" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-16-01044" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-16-01044" ref-type="bibr">33</xref>]. However, despite their increasing prevalence, their translation into clinical therapeutics remains limited [<xref rid="B34-pharmaceutics-16-01044" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-16-01044" ref-type="bibr">35</xref>].</p><p>Alternatively, empirical mathematical functions, devoid of physiological or compartmental underpinnings, have been employed in EHC modeling [<xref rid="B36-pharmaceutics-16-01044" ref-type="bibr">36</xref>]. The pioneering model in EHC employed two gamma functions to fit the plasma mycophenolic acid profile, while another model utilized the sum of two Gaussian functions to depict the plasma profile of simvastatin. Demonstrated feasibility extends these models beyond two peaks by incorporating additional terms [<xref rid="B37-pharmaceutics-16-01044" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-16-01044" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-16-01044" ref-type="bibr">39</xref>]. While these models may not elucidate EHC&#8217;s underlying processes, they align with experimental data and capture the secondary peak characteristics of EHC. Consequently, they have found widespread implementation in clinical settings as valuable tools in therapeutic drug monitoring (TDM).</p><p>Understanding the magnitude of EHC for drugs assumes paramount importance, as it significantly influences key pharmacokinetic parameters such as clearance (<inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>), volume of distribution (<inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>V</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>), half-life plasma (<inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>), and <inline-formula><mml:math id="mm4" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> [<xref rid="B40-pharmaceutics-16-01044" ref-type="bibr">40</xref>]. Precisely, the <inline-formula><mml:math id="mm5" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> is frequently used in TDM for dose adjustment in drugs with a narrow therapeutic range [<xref rid="B41-pharmaceutics-16-01044" ref-type="bibr">41</xref>]. Sampling times and the number of samples are a limiting factor in TDM that requires restricting the sampling strategy. On the other hand, the <inline-formula><mml:math id="mm6" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> is an essential parameter in bioequivalence studies, and it has been argued that the conventional trapezoidal method, used to calculate the <inline-formula><mml:math id="mm7" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, probably overestimates its value when EHC exists.</p><p>The debate over whether empirical models offer advantages over traditional methods, like the trapezoidal rule, in estimating <inline-formula><mml:math id="mm8" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> remains unresolved. Thus, this study aims to evaluate the efficacy of several empirical models in characterizing time&#8211;concentration profiles of hypothetical and real drugs sharing the trait of undergoing EHC. This evaluation, grounded in simulations of various pharmacokinetic scenarios, aims to shed light on the potential of empirical models in understanding and quantifying EHC&#8217;s impact from both conventional and limited sampling perspectives.</p></sec><sec id="sec2-pharmaceutics-16-01044"><title>2. Materials and Methods</title><p>A compartmental model and a set of empirical models were developed. The compartmental model was used to perform simulations of different pharmacokinetic scenarios; the empirical models were used to estimate the <inline-formula><mml:math id="mm9" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of these simulations.</p><sec id="sec2dot1-pharmaceutics-16-01044"><title>2.1. Compartmental Pharmacokinetic Model</title><p>The compartmental model was built considering the kinetic processes involved in EHC, in addition to those that can occur in parallel and that contribute to global pharmacokinetics; see <xref rid="pharmaceutics-16-01044-f001" ref-type="fig">Figure 1</xref>a.</p><p>The behavior of the EHC phenomenon is schematized in <xref rid="pharmaceutics-16-01044-f001" ref-type="fig">Figure 1</xref>b and is given the following system of differential equations:<disp-formula id="FD1-pharmaceutics-16-01044"><label>(1)</label><mml:math id="mm10" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="" open="{"><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>G</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>G</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>S</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>B</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>G</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>G</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>D</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
where <inline-formula><mml:math id="mm11" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>x</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the concentration of drug and whose subscript indicates the site in which it is located (<inline-formula><mml:math id="mm12" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> central compartment; <inline-formula><mml:math id="mm13" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> peripheral; <inline-formula><mml:math id="mm14" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>G</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> intestinal; <inline-formula><mml:math id="mm15" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>B</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> biliary; <inline-formula><mml:math id="mm16" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> in the solid pharmaceutical form). Except for the parameters <inline-formula><mml:math id="mm17" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm18" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="mm19" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, which are set as parameters as a function of time or drug concentration, most of the parameters in this system of equations are constant during the simulation.</p><p>Fraction of dissolved dose of solid dosage form (<inline-formula><mml:math id="mm20" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>) is one of the time-dependent parameters and was simulated with the Weibull function in Equation (2). This is a function without a physicochemical basis widely used in modeling drug dissolution [<xref rid="B42-pharmaceutics-16-01044" ref-type="bibr">42</xref>], and it is expressed as follows:<disp-formula id="FD6-pharmaceutics-16-01044"><label>(2)</label><mml:math id="mm21" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:msup><mml:mrow><mml:mfenced><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced></mml:mrow><mml:mi>a</mml:mi></mml:msup></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
where <inline-formula><mml:math id="mm22" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> corresponds to the time it takes to start the dissolution process, <inline-formula><mml:math id="mm23" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the scale parameter that determines the fraction of drug released from the formulation, and <inline-formula><mml:math id="mm24" overflow="scroll"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:math></inline-formula> is the shape parameter that characterizes the curve as exponential (<inline-formula><mml:math id="mm25" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), sigmoid (<inline-formula><mml:math id="mm26" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), or parabolic (<inline-formula><mml:math id="mm27" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>).</p><p>Emptying of the gallbladder (<inline-formula><mml:math id="mm28" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>) is a time-dependent parameter; continuous function, given by Equation (3), was used to simulate emptying of the gallbladder and allows the generation of several emptying cycles distributed over a period of 24 h; it is expressed in the following way:<disp-formula id="FD7-pharmaceutics-16-01044"><label>(3)</label><mml:math id="mm29" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mstyle displaystyle="true"><mml:munderover><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8721;</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>b</mml:mi><mml:msup><mml:mrow><mml:mfenced><mml:mrow><mml:mi>sin</mml:mi><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>&#960;</mml:mi><mml:mfenced><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>24</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
where the parameter <inline-formula><mml:math id="mm30" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the maximum emptying speed of the gallbladder, the parameter <inline-formula><mml:math id="mm31" overflow="scroll"><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:math></inline-formula> is related to the duration of each of the emptying cycles, and the parameter <inline-formula><mml:math id="mm32" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> allows the establishment of the moments in which the emptying of gallbladder occurs for each of the EHC cycles according to meal times (established as hours elapsed after drug intake).</p><p>The last non-constant parameter <inline-formula><mml:math id="mm33" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is a function of the drug concentration in the central compartment and represents the biotransformation rate of the drug. For its calculation, the Michaelis&#8211;Menten equation, Equation (4), is used. This equation allows us to consider the effects of the competition that may exist between biotransformation and other processes that the drug may have (bile transfer, transfer to the peripheral compartment, or renal elimination), and it is expressed as follows:<disp-formula id="FD8-pharmaceutics-16-01044"><label>(4)</label><mml:math id="mm34" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>C</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
where <inline-formula><mml:math id="mm35" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the Michaelis&#8211;Menten constant, and <inline-formula><mml:math id="mm36" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is the maximum biotransformation rate.</p><p>To complete the analysis, the percentage of drugs within the central compartment undergoing enterohepatic circulation was calculated. This percentage is not necessarily constant over time; Equation (5) allows the calculation of its temporal fluctuation, while Equation (6) calculates its theoretical maximum value.
<disp-formula id="FD9-pharmaceutics-16-01044"><label>(5)</label><mml:math id="mm37" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mo>%</mml:mo><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD10-pharmaceutics-16-01044"><label>(6)</label><mml:math id="mm38" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>%</mml:mo><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot2-pharmaceutics-16-01044"><title>2.2. Compartmental Model Assumptions</title><p>The compartmental model was developed with the objective of representing the EHC and some parallel pharmacokinetic processes in the most realistic way possible; however, to simplify the analysis, some reasonable assumptions are made:<list list-type="roman-lower"><list-item><p>Compartments are homogeneous, so drug concentration within each of the compartments reaches an instantaneous kinetic equilibrium;</p></list-item><list-item><p>Liver is located within the central compartment, so there is an instantaneous kinetic equilibrium between plasma and intrahepatic drug concentrations;</p></list-item><list-item><p>Elimination by routes other than renal, fecal, or biotransformation is insignificant;</p></list-item><list-item><p>Fraction of drug that is biotransformed does not need to be reconverted to the original drug to undergo EHC, as this usually happens under the presence of microbiota glucuronidases;</p></list-item><list-item><p>Elimination by biotransformation occurs through a single pathway involving a single enzyme;</p></list-item><list-item><p>Drug dissolved in the bile is excreted to the intestinal compartment only from the bile compartment, so direct excretion from the central compartment is non-existent;</p></list-item><list-item><p>Fraction of drug dissolved, transfer of drug from the gallbladder to the intestine, and rate of biotransformation can be realistically represented by equations, while the rest of the parameters follow first-order kinetics that do not consider changes in transport rates between compartments due to physiological phenomena.</p></list-item></list></p><p>Finally, during simulations, it was assumed that the gallbladder is only activated by meals three times during a 24-hour period; at other times, its emptying is null.</p></sec><sec id="sec2dot3-pharmaceutics-16-01044"><title>2.3. Pharmacokinetic Simulations</title><p>The compartmental model was implemented through the SimBiology tool of MATLAB version R2021a. Drug concentrations versus time were simulated with the sundials solvertype. The description, units, and specific values of model parameters are shown in <xref rid="pharmaceutics-16-01044-t001" ref-type="table">Table 1</xref>. These values were proposed to have a starting model for subsequent scenarios.</p><p>Data shown in <xref rid="pharmaceutics-16-01044-t001" ref-type="table">Table 1</xref> correspond to those of the standard model from which the values of one parameter were varied at a time to generate 18 different scenarios. These scenarios are grouped into pairs that differ in whether the value of the modified parameter is greater or less than its value in the standard model. <xref rid="pharmaceutics-16-01044-t002" ref-type="table">Table 2</xref> shows the description, the modified parameter, and its value in each scenario.
<table-wrap position="anchor" id="pharmaceutics-16-01044-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t001_Table 1</object-id><label>Table 1</label><caption><p>Parameters of the standard model.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Units</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm249" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.9</td><td align="center" valign="middle" rowspan="1" colspan="1">Intestinal absorption rate</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm250" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Renal elimination rate</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm251" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Fecal elimination rate</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm252" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">See Equation (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">Dissolved drug fraction</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm253" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Scale parameter of the Weibull function</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm254" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">Weibull function delay time</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm255" overflow="scroll"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">Shape parameter of the Weibull function</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm256" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">See Equation (3)</td><td align="center" valign="middle" rowspan="1" colspan="1">Rate of transfer from gallbladder to intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm257" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">Maximum transfer rate from gallbladder to intestine</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm258" overflow="scroll"><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">300</td><td align="center" valign="middle" rowspan="1" colspan="1">Biliary emptying cycle duration parameter</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm259" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">5, 11, 17</td><td align="center" valign="middle" rowspan="1" colspan="1">Times of maximum gallbladder emptying rate</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm260" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">Transfer rate from central to peripheral compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm261" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">Transfer rate from peripheral to central compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm262" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">mg/h</td><td align="center" valign="middle" rowspan="1" colspan="1">See Equation (4)</td><td align="center" valign="middle" rowspan="1" colspan="1">Instantaneous biotransformation rate</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm263" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">mg/h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Maximum biotransformation rate</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm264" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">mg/L</td><td align="center" valign="middle" rowspan="1" colspan="1">See <xref rid="pharmaceutics-16-01044-t003" ref-type="table">Table 3</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">Michaelis&#8211;Menten constant for biotransformation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm265" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">h<sup>&#8722;1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">See <xref rid="pharmaceutics-16-01044-t003" ref-type="table">Table 3</xref></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transfer rate from the central compartment to the gallbladder</td></tr></tbody></table></table-wrap>
<table-wrap position="anchor" id="pharmaceutics-16-01044-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t002_Table 2</object-id><label>Table 2</label><caption><p>Modified parameters in pharmacokinetic scenarios.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Scenarios</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm266" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">k</mml:mi><mml:mi mathvariant="bold-italic">m</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:math></inline-formula>&#160;<sup>a</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm267" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">k</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">h</mml:mi><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:math></inline-formula>&#160;<sup>a</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm268" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm269" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Rapid absorption in the intestinal compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm270" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Slow absorption in the intestinal compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm271" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm272" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">B</td><td align="center" valign="middle" rowspan="1" colspan="1">Rapid renal elimination from central compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm273" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">III</td><td align="center" valign="middle" rowspan="1" colspan="1">C</td><td align="center" valign="middle" rowspan="1" colspan="1">Slow renal elimination from central compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm274" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm275" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Rapid elimination from intestinal compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm276" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>6</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Slow elimination from intestinal compartment</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm277" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>7</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm278" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">0.0</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Drug release without delay time</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm279" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Time-delayed drug release</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm280" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>9</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm281" overflow="scroll"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Parabolic drug release</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm282" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Sigmoidal drug release</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm283" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm284" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">6.0</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Rapid gallbladder emptying</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm285" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Slow gallbladder emptying</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm286" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">B</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">600</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Short gallbladder emptying duration</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm287" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>14</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Long gallbladder emptying duration</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm288" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm289" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>&#160;</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">1.0, 0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">II</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">Fast peripheral distribution with slow central return</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm290" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>16</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1, 1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">I</td><td align="center" valign="middle" rowspan="1" colspan="1">E</td><td align="center" valign="middle" rowspan="1" colspan="1">Slow peripheral distribution with fast central return</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm291" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>17</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm292" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" rowspan="1" colspan="1">A</td><td align="center" valign="middle" rowspan="1" colspan="1">Broad first pass elimination</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm293" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>18</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced first pass removal</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Values of <inline-formula><mml:math id="mm294" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm44" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> are grouped in different cases represented by Roman numerals and capital letters, respectively; see <xref rid="pharmaceutics-16-01044-t003" ref-type="table">Table 3</xref>.</p></fn></table-wrap-foot></table-wrap>
<table-wrap position="anchor" id="pharmaceutics-16-01044-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t003_Table 3</object-id><label>Table 3</label><caption><p>Values of the constants <inline-formula><mml:math id="mm295" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm45" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and their effect on the percentage of drugs that undergo EHC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="center" valign="middle" style="border-top:solid thin" rowspan="1"><italic toggle="yes">k<sub>m</sub></italic></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Effect on<break/><italic toggle="yes">EHC</italic>% <sup>a</sup></th><th colspan="5" align="center" valign="middle" style="border-top:solid thin" rowspan="1"><italic toggle="yes">k<sub>ehc</sub></italic></th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1"><italic toggle="yes">EHC<sub>max</sub></italic>%</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">+</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0666</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3333</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0133</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7333</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1333</td><td align="center" valign="middle" rowspan="1" colspan="1">20%</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">++</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">1.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">60%</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+++</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80%</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> The effect is observed as a decrease with respect to the maximum value: insignificant decrease: +; moderate decrease: ++; outstanding decrease: +++.</p></fn></table-wrap-foot></table-wrap>
</p><p>To increase the diversity of the data generated in each scenario, the values of the parameters <inline-formula><mml:math id="mm39" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm40" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, which are related to the magnitude of the EHC, were varied. <xref rid="pharmaceutics-16-01044-t003" ref-type="table">Table 3</xref> shows the values of <inline-formula><mml:math id="mm41" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm42" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> for each of the cases and their effect on the EHC. Different combinations of these two parameters allowed the generation of up to nine different simulations per scenario, giving a total of one hundred and sixty-two simulations. At the end of each simulation, post-simulation calculations were performed to obtain the <inline-formula><mml:math id="mm43" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>.</p><p>From each simulation, time versus plasma concentration data were extracted at specific times to represent the sampling process. The sampling schemes were divided into three categories, which are shown in <xref rid="pharmaceutics-16-01044-t004" ref-type="table">Table 4</xref>.</p></sec><sec id="sec2dot4-pharmaceutics-16-01044"><title>2.4. Empirical Pharmacokinetic Models</title><p>The empirical models were fitted to the data extracted from each simulation. Five models (<inline-formula><mml:math id="mm46" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> to <inline-formula><mml:math id="mm47" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>) represented by functions were built to characterize the multiple peaks present in the EHC. They were compared with each other and with respect to the reference model of extravascular administration (<inline-formula><mml:math id="mm48" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), Equation (7). Equations (8) and (9) are modifications of previously reported models [<xref rid="B37-pharmaceutics-16-01044" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-16-01044" ref-type="bibr">38</xref>], while the rest, Equations (10)&#8211;(12), are new models built intuitively. They are described as:<disp-formula id="FD11-pharmaceutics-16-01044"><label>(7)</label><mml:math id="mm49" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:mfenced><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>b</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>&#8722;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD12-pharmaceutics-16-01044"><label>(8)</label><mml:math id="mm50" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:msup><mml:mi>t</mml:mi><mml:mi>c</mml:mi></mml:msup><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>b</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8721;</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mfenced><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:msup><mml:mrow><mml:mfenced><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD13-pharmaceutics-16-01044"><label>(9)</label><mml:math id="mm51" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>a</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mstyle displaystyle="true"><mml:munderover><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8721;</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mfenced><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="sans-serif">&#915;</mml:mi><mml:mfenced><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mstyle><mml:msubsup><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8747;</mml:mo></mml:mstyle><mml:mn>0</mml:mn><mml:mrow><mml:mi>t</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:msubsup><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD14-pharmaceutics-16-01044"><label>(10)</label><mml:math id="mm52" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:mi>t</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>a</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mstyle displaystyle="true"><mml:munderover><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8721;</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mfenced><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mfenced close="" open="{"><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mfenced><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD15-pharmaceutics-16-01044"><label>(11)</label><mml:math id="mm53" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mstyle displaystyle="true"><mml:munderover><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8721;</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mfenced><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mfenced close="" open="{"><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>c</mml:mi><mml:mfenced><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>c</mml:mi><mml:mfenced><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8805;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD16-pharmaceutics-16-01044"><label>(12)</label><mml:math id="mm54" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>c</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mstyle displaystyle="true"><mml:munderover><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8721;</mml:mo></mml:mstyle><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>&#8734;</mml:mo></mml:munderover></mml:mstyle><mml:mstyle displaystyle="true"><mml:munderover><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>&#8721;</mml:mo></mml:mstyle><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mfenced><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>c</mml:mi><mml:mn>24</mml:mn><mml:mi>j</mml:mi><mml:mo>&#8722;</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mfenced><mml:mrow><mml:mn>24</mml:mn><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfenced><mml:mfenced><mml:mrow><mml:mi>ln</mml:mi><mml:mfenced><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mi>c</mml:mi><mml:mfenced><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:msup><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mfenced close="" open="{"><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>c</mml:mi><mml:mfenced><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:mn>24</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>c</mml:mi><mml:mfenced><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:mn>24</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:mn>24</mml:mn><mml:mi>j</mml:mi><mml:mo>&#8805;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:mn>24</mml:mn><mml:mi>j</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
where the letters <inline-formula><mml:math id="mm55" overflow="scroll"><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm56" overflow="scroll"><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm57" overflow="scroll"><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm58" overflow="scroll"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:math></inline-formula>, etc., are the parameters of the models; <inline-formula><mml:math id="mm59" overflow="scroll"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:math></inline-formula> is the time and <inline-formula><mml:math id="mm60" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mfenced><mml:mi>t</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math></inline-formula> the plasma concentration estimated by each model. Except for the model given by Equation (1), the models are built with summations that describe the first absorption peak (when <inline-formula><mml:math id="mm61" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>) and secondary resorption peaks caused by EHC (when <inline-formula><mml:math id="mm62" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>); therefore, in these models, the number of peaks is equal to <inline-formula><mml:math id="mm63" overflow="scroll"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula>. Another characteristic that all models have in common is that they incorporate a term or factor to the left of the sum and that characterizes the elimination process.</p><p>The model described by Equation (12) is an extension of the model in Equation (11) and is intended to predict the presence of additional peaks that may not be detected after the first 24 h. This prediction is made under the assumption that the gallbladder will empty with an intensity and at a time like the first day. In this model, the intensity and moment of gallbladder emptying are given by the parameters <inline-formula><mml:math id="mm64" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm65" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, respectively. The prediction after 24 h is based on the parameters that describe the largest peak (usually the first absorption peak, <inline-formula><mml:math id="mm66" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm67" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>) and the last observed peak (<inline-formula><mml:math id="mm68" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>b</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm69" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>).</p><p>The <inline-formula><mml:math id="mm70" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> of all models converge to a finite value when the model is fitted to time versus concentration data; its value can be calculated exactly using explicit formulas. <xref rid="app1-pharmaceutics-16-01044" ref-type="app">Equations (S1)&#8211;(S6)</xref> shown in the <xref rid="app1-pharmaceutics-16-01044" ref-type="app">Supplementary Materials (Supplementary Data S1)</xref> allow us to perform this calculation exactly, and they were obtained with the help of Maple software version 2018.</p></sec><sec id="sec2dot5-pharmaceutics-16-01044"><title>2.5. Compilation of Pharmacokinetic Profiles from the Literature</title><p>A bibliographic search and compilation of pharmacokinetic profiles of drugs that undergo EHC reported in different works was carried out. The search criteria were drugs administered orally, in a single dose, and with a profile with at least two clearly visible peaks. WebPlotDigitizer version 4.5 software was used to recover time and plasma concentration data from the graph reported in the study. The software allows you to select the points in the pharmacokinetic profile to estimate the values of the time&#8211;concentration data pairs. This software has been used successfully for data collection from graphs [<xref rid="B43-pharmaceutics-16-01044" ref-type="bibr">43</xref>].</p></sec><sec id="sec2dot6-pharmaceutics-16-01044"><title>2.6. Data Fitting, Statistical Analysis, and Evaluation of Empirical Models</title><p>Non-linear regression (NLR) of the simulated data retrieved from the literature was performed using the Curve Fitting tool of MATLAB version R2021a. When necessary, restrictions were applied to the coefficients to obtain a good parametric fit. The adjusted <inline-formula><mml:math id="mm71" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm72" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="mm73" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> error metrics were obtained directly from said tool. The script used to execute the NLR is provided in the <xref rid="app1-pharmaceutics-16-01044" ref-type="app">Supplementary Materials (Supplementary Data S2)</xref>.</p><p>Evaluation of models was carried out with the corrected Akaike Criterion (<inline-formula><mml:math id="mm74" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>) for small sample sizes using Equation (13):<disp-formula id="FD17-pharmaceutics-16-01044"><label>(13)</label><mml:math id="mm75" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mi>n</mml:mi><mml:mi>ln</mml:mi><mml:mfenced><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>S</mml:mi><mml:mi>S</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mfenced><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>k</mml:mi><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
where <inline-formula><mml:math id="mm76" overflow="scroll"><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:math></inline-formula> is the number of model parameters, and <inline-formula><mml:math id="mm77" overflow="scroll"><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> is the number of observations.</p><p>As part of evaluation of the models, comparisons were made between the reference <inline-formula><mml:math id="mm78" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> of the simulation, with the <inline-formula><mml:math id="mm79" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> calculated by the trapezoidal method and estimated by empirical models, Equations (S1)&#8211;(S6).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-16-01044"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-16-01044"><title>3.1. Effect of EHC Degree on AUC</title><p>Initially, we aimed to verify whether the compartmental model could accurately simulate the EHC process, allowing us to investigate its impact on <inline-formula><mml:math id="mm80" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. Simulations following single-dose extravascular administration delineated the relationship between gallbladder emptying, gallbladder drug concentrations, and plasma profile (<xref rid="pharmaceutics-16-01044-f002" ref-type="fig">Figure 2</xref>). Notably, spikes in plasma profile coincided with gallbladder contractions, underscoring the dynamic nature of EHC. Additionally, drugs subject to extensive EHC (depicted by the black line) exhibited prolonged residence in the organism compared to those experiencing minimal EHC (illustrated by the yellow line).</p><p>Expanding our model to encompass biotransformation and gallbladder transport enabled us to assess the influence of their interplay. Simulations with a <inline-formula><mml:math id="mm81" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> revealed a consistent EHC% value (bold lines, left panel of <xref rid="pharmaceutics-16-01044-f003" ref-type="fig">Figure 3</xref>), suggesting negligible competition. Conversely, simulations with <inline-formula><mml:math id="mm82" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0.005</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> yielded fluctuating EHC% values, ranging between a minimum and a theoretical maximum determined by Equation (6) (pale lines, right panel of <xref rid="pharmaceutics-16-01044-f003" ref-type="fig">Figure 3</xref>), indicative of significant competition. In this scenario, maximum EHC% values ranged from 88% to 33%. This competitive dynamic directly impacted <inline-formula><mml:math id="mm83" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, where cases of negligible competition yielded higher maximum values (ranging from 20.2 to 30.9 mg &#215; h/L) compared to scenarios with relevant competition, where <inline-formula><mml:math id="mm84" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> decreased with decreasing <inline-formula><mml:math id="mm85" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> values. These findings affirm the completeness and realistic simulation capabilities of our model to simulate the EHC process.</p></sec><sec id="sec3dot2-pharmaceutics-16-01044"><title>3.2. Simulation of Pharmacokinetic Scenarios and Fitting to Empirical Models</title><p>We conducted 162 simulations across eighteen scenarios to explore their impact on <inline-formula><mml:math id="mm86" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, as summarized in <xref rid="pharmaceutics-16-01044-t005" ref-type="table">Table 5</xref>. Comparative analysis revealed that scenarios S1 through <inline-formula><mml:math id="mm87" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>6</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm88" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> exhibited significantly different <inline-formula><mml:math id="mm89" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> compared to standard model <inline-formula><mml:math id="mm90" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>7</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. Additional details and pharmacokinetic simulation plots for each scenario are available in the <xref rid="app1-pharmaceutics-16-01044" ref-type="app">Supplementary Materials (Supplementary Data S3, Figures S1&#8211;S18)</xref>.</p><p>Next, we fitted six empirical models to the obtained plasma profile data. <xref rid="pharmaceutics-16-01044-f004" ref-type="fig">Figure 4</xref> illustrates the fit of these models to the data from a representative simulation. Apart from model <inline-formula><mml:math id="mm108" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, all models successfully captured the multiple peaks of the plasma profile, exhibiting subtle visual differences.</p><p>Criteria for selecting the best model included adjusted <inline-formula><mml:math id="mm109" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula>, AICc, and accuracy in predicting <inline-formula><mml:math id="mm110" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. <xref rid="pharmaceutics-16-01044-f005" ref-type="fig">Figure 5</xref> displays scatter plots of these criteria, while <xref rid="pharmaceutics-16-01044-t006" ref-type="table">Table 6</xref> presents their means for each model. <xref rid="pharmaceutics-16-01044-f005" ref-type="fig">Figure 5</xref> allows the visual identification of the result of each regression of the empirical models in a scatter plot. Models <inline-formula><mml:math id="mm111" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> (cyan balls) and <inline-formula><mml:math id="mm112" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> (red balls) stand out for showing a higher degree of clustering than other models, and both models have the lowest AICc values and the highest adjusted <inline-formula><mml:math id="mm113" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> values. The gamma distribution model (pink balls) presented poorer clustering due to the greater difficulty of performing reproducible regressions since, in this model, applying restrictions for a successful NLR was less intuitive for the authors.</p><p>Model <inline-formula><mml:math id="mm114" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> achieved the highest values for adjusted <inline-formula><mml:math id="mm115" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> (0.979), <inline-formula><mml:math id="mm116" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> (&#8722;58.1), and accuracy in predicting <inline-formula><mml:math id="mm117" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> (105.9). Although <inline-formula><mml:math id="mm118" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> exhibited the smallest spread in adjusted <inline-formula><mml:math id="mm119" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> (&#177;0.02), it also had the highest spread in <inline-formula><mml:math id="mm120" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> prediction accuracy (&#177;21.4). These results indicate that <inline-formula><mml:math id="mm121" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> demonstrated the best performance characteristics and was thus chosen for subsequent analysis.</p></sec><sec id="sec3dot3-pharmaceutics-16-01044"><title>3.3. Estimation of AUC in Different Pharmacokinetic Scenarios</title><p>Applicability of model <inline-formula><mml:math id="mm122" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> to various pharmacokinetic scenarios was examined. Results indicated that model <inline-formula><mml:math id="mm123" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> accurately predicted <inline-formula><mml:math id="mm124" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> for most scenarios, with close to 100% accuracy (<xref rid="pharmaceutics-16-01044-f006" ref-type="fig">Figure 6</xref>). However, scenarios <inline-formula><mml:math id="mm125" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> (rapid renal elimination from central compartment) and <inline-formula><mml:math id="mm126" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> (fast peripheral distribution with slow central return) notably overestimated the actual <inline-formula><mml:math id="mm127" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> (exceeding 110% and 150%, respectively). This overestimation persisted regardless of whether the trapezoidal method or model <inline-formula><mml:math id="mm128" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> was employed.</p></sec><sec id="sec3dot4-pharmaceutics-16-01044"><title>3.4. Estimation of AUC under Different Sampling Schemes</title><p>Next, we investigated the impact of sampling schemes on predictions of model <inline-formula><mml:math id="mm129" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>. Firstly, we contrasted meal-based and conventional sampling methods (<xref rid="pharmaceutics-16-01044-f007" ref-type="fig">Figure 7</xref>). Notably, when the percentage of drugs undergoing EHC was 40%, model-predicted <inline-formula><mml:math id="mm130" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> accuracy was nearly 100% for both sampling schemes. However, at 80% EHC, accuracy decreased to approximately 50% with conventional sampling, while remaining close to 100% with meal-based sampling. Regardless of the sampling scheme or the percentage of drugs undergoing EHC, <inline-formula><mml:math id="mm131" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> estimates by the trapezoidal method closely mirrored those by the model.</p><p>Secondly, different sampling schemes for TDM were assessed (<xref rid="pharmaceutics-16-01044-f008" ref-type="fig">Figure 8</xref>). It was observed that with TDM1 and TDM2 schemes, model-predicted <inline-formula><mml:math id="mm132" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> accuracy ranged between 50&#8211;75%, depending on the percentage of drugs undergoing EHC. In contrast, TDM3 and TDM4 schemes notably improved accuracy to over 75%, while TDM5 showed a modest increase. Notably, <inline-formula><mml:math id="mm133" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> predictions by the model were nearly identical with TDM1/TDM2 and TDM3/TDM4 schemes, respectively. In all cases, <inline-formula><mml:math id="mm134" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> estimates by the trapezoidal method improved gradually with increased sampling times.</p></sec><sec id="sec3dot5-pharmaceutics-16-01044"><title>3.5. Application of Model M5</title><p>Fourteen average plasma profiles of drugs undergoing EHC were gathered from the literature [<xref rid="B44-pharmaceutics-16-01044" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-16-01044" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-16-01044" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-16-01044" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-16-01044" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-16-01044" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-16-01044" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-16-01044" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-16-01044" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-16-01044" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-16-01044" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-16-01044" ref-type="bibr">55</xref>,<xref rid="B56-pharmaceutics-16-01044" ref-type="bibr">56</xref>], and model <inline-formula><mml:math id="mm135" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> was applied to fit these profiles. Additional graphs provided in the <xref rid="app1-pharmaceutics-16-01044" ref-type="app">Supplementary Materials</xref> illustrate the fit of model M5 to data extracted from representative pharmacokinetic profiles (<xref rid="app1-pharmaceutics-16-01044" ref-type="app">Supplementary Data S4, Figures S19&#8211;S28</xref>).</p><p>The <inline-formula><mml:math id="mm136" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> was estimated using model <inline-formula><mml:math id="mm137" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> and compared with reported values, as shown in <xref rid="pharmaceutics-16-01044-f009" ref-type="fig">Figure 9</xref>, obtaining a correspondence between both values close to 100%. The largest discrepancies were observed for Ezetimibe and Meloxicam, with differences of 78.4% and 124.1%, respectively, while other estimates fell within the range of 80&#8211;120%, as depicted in <xref rid="pharmaceutics-16-01044-t007" ref-type="table">Table 7</xref>.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-16-01044"><title>4. Discussion</title><sec id="sec4dot1-pharmaceutics-16-01044"><title>4.1. Effect of EHC Degree on AUC</title><p>Simulations of our compartmental model are in agreement with other studies in which it is stated that the EHC increases the permanence of the drug in the body by increasing <inline-formula><mml:math id="mm138" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> apparent elimination [<xref rid="B40-pharmaceutics-16-01044" ref-type="bibr">40</xref>,<xref rid="B57-pharmaceutics-16-01044" ref-type="bibr">57</xref>]. We want to highlight the linear nature of our compartmental model in which an increase in dose proportionally increases <inline-formula><mml:math id="mm139" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> regardless of the degree of EHC% (<xref rid="app1-pharmaceutics-16-01044" ref-type="app">Supplementary Data S5, Figure S29</xref>). This is not surprising considering that drugs such as atorvastatin and mycophenolic acid that experience EHC maintain linear pharmacokinetics with respect to <inline-formula><mml:math id="mm140" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> [<xref rid="B58-pharmaceutics-16-01044" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-16-01044" ref-type="bibr">59</xref>]. However, a less understood effect of the EHC is its impact on <inline-formula><mml:math id="mm141" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. We take advantage of the information generated from the simulations to address a question that has been discussed in other works.</p><p>It has been discussed on several occasions how <inline-formula><mml:math id="mm142" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> is altered when the drug undergoes EHC. The prevailing position is that <inline-formula><mml:math id="mm143" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> increases when EHC exists; several papers have provided evidence to support this position [<xref rid="B60-pharmaceutics-16-01044" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-16-01044" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-16-01044" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-16-01044" ref-type="bibr">63</xref>]. However, in other studies, it has been proposed that the degree of EHC does not have an impact on <inline-formula><mml:math id="mm144" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> [<xref rid="B57-pharmaceutics-16-01044" ref-type="bibr">57</xref>,<xref rid="B64-pharmaceutics-16-01044" ref-type="bibr">64</xref>]. Recently, Ibarra et al. reported that the inclusion of a hepatic compartment, where the competition between hepatobiliary secretion and biotransformation is explicit, allows us to explain within their model why the level of <inline-formula><mml:math id="mm145" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> increases when the degree of EHC is higher [<xref rid="B40-pharmaceutics-16-01044" ref-type="bibr">40</xref>]. Similar to the model proposed by Ibarra, in our model, this competition is considered with the difference that the elimination constant by biotransformation is not of the first order but follows Michaelis&#8211;Menten kinetics.</p><p>For drugs with a very large <inline-formula><mml:math id="mm146" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>, the rate of elimination by biotransformation (<inline-formula><mml:math id="mm147" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>) is negligible, but when the <inline-formula><mml:math id="mm148" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> rate is very small, <inline-formula><mml:math id="mm149" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> increases, and the competition between bile secretion and biotransformation becomes important. When this happens, <inline-formula><mml:math id="mm150" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> is reached more quickly due to the drug&#8217;s high affinity for the enzyme. As described above, the competition between the two processes causes a fluctuation of <inline-formula><mml:math id="mm151" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> between a theoretical minimum and a theoretical maximum. The maximum can be estimated with Equation (6), while Equation (14) allows estimating the minimum possible for <inline-formula><mml:math id="mm152" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:mi>C</mml:mi><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, which is reached if the concentration of drug in the compartment is high enough.
<disp-formula id="FD39-pharmaceutics-16-01044"><label>(14)</label><mml:math id="mm153" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mtable equalrows="true" equalcolumns="true"><mml:mtr><mml:mtd><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>%</mml:mo><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p><p><xref rid="pharmaceutics-16-01044-f003" ref-type="fig">Figure 3</xref> shows that <inline-formula><mml:math id="mm154" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of drug is lower at <inline-formula><mml:math id="mm155" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> equal to 88% compared to those with <inline-formula><mml:math id="mm156" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> equal to 33%. Within the proposed model, this is explained by the fact that biliary transport behaves as an additional elimination pathway that results in a decrease in <inline-formula><mml:math id="mm157" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> by the amount of the drug extracted from the central compartment.</p><p>According to our model, we can differentiate two ways that increase <inline-formula><mml:math id="mm158" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> by altering the degree of EHC that a drug undergoes. The first is by decreasing <inline-formula><mml:math id="mm159" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> of biotransforming enzyme by adding a competitor, and the second is by suppressing drug transport into the gallbladder by decreasing the value of <inline-formula><mml:math id="mm160" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. We translate these two possibilities into a couple of examples.</p><p>In the first case, it could happen that a drug that is subjected to EHC and to biotransformation is administered concomitantly with another drug that is also biotransformed by the same enzyme (e.g., CYP3A4). Competition of both substrates for the same enzyme will increase <inline-formula><mml:math id="mm161" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>&#160;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> of the drug that EHC is experiencing. As shown in <xref rid="pharmaceutics-16-01044-f003" ref-type="fig">Figure 3</xref>, high values of <inline-formula><mml:math id="mm162" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>&#160;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> increase <inline-formula><mml:math id="mm163" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. In fact, simvastatin, a drug that undergoes EHC, and cyclosporine are biotransformed by the same enzyme CYP3A4; when administered concomitantly, the body&#8217;s exposure to simvastatin increases enough to give rise to the toxic effects of simvastatin [<xref rid="B65-pharmaceutics-16-01044" ref-type="bibr">65</xref>].</p><p>In the second case, a drug could be presented that undergoes EHC in the normal population, but where a mutation in the gene encoding a protein responsible for drug transport to the biliary canniculus (e.g., MRP2) is able to decrease the activity of the transporter in carriers of the mutation. According to our model, this mutation would imply a decrease in <inline-formula><mml:math id="mm164" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:mi>H</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>%</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and an increase in <inline-formula><mml:math id="mm165" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> with respect to the normal population. In fact, people who suffer from the so-called Dubin&#8211;Johnson syndrome have higher levels of bilirubin in plasma than a normal person because the MRP2 transporter is defective, preventing bilirubin from experiencing enterohepatic circulation to which it is normally subjected, which causes its accumulation within the body [<xref rid="B66-pharmaceutics-16-01044" ref-type="bibr">66</xref>].</p><p>In summary, suppressing biliary transport or favoring biliary transport over biotransformation could increase <inline-formula><mml:math id="mm166" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of drugs from two different perspectives. In one study, both perspectives were investigated and reached conclusions similar to those of our model [<xref rid="B67-pharmaceutics-16-01044" ref-type="bibr">67</xref>], but more studies are still needed to investigate how much of the <inline-formula><mml:math id="mm167" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> increase observed in these cases can be attributed to the modification of the EHC.</p></sec><sec id="sec4dot2-pharmaceutics-16-01044"><title>4.2. Simulation of Pharmacokinetic Scenarios and Fit to Empirical Models</title><p>In addition to the biliary transfer rate (<inline-formula><mml:math id="mm168" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>h</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>), we can point out from <xref rid="pharmaceutics-16-01044-t005" ref-type="table">Table 5</xref> that the parameters related to absorption (<inline-formula><mml:math id="mm169" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, renal elimination (<inline-formula><mml:math id="mm170" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, intestinal elimination (<inline-formula><mml:math id="mm171" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, and transport between compartments (<inline-formula><mml:math id="mm172" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> y <inline-formula><mml:math id="mm173" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> were the ones that most influenced the modification of <inline-formula><mml:math id="mm174" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> with respect to the standard model. Regardless of the effect that these processes may have, all of them have the characteristic pharmacokinetic profile of &#8220;sawtooth&#8221;, a sufficient requirement for their adjustment to empirical models.</p><p>A qualitative analysis of <xref rid="pharmaceutics-16-01044-f004" ref-type="fig">Figure 4</xref> reveals that except for the classical model of extravascular administration (<inline-formula><mml:math id="mm175" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>), most models can capture the multi-peak phenomenon, although with some differences. For example, the model <inline-formula><mml:math id="mm176" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> generated symmetric peaks, while the rest of the models generated asymmetric peaks more similar to those in the simulation. The models <inline-formula><mml:math id="mm177" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm178" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> presented a smooth transition from one peak to the next, while in the rest of these models, the transition was more abrupt. The models <inline-formula><mml:math id="mm179" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm180" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> tended to overestimate the magnitude of some of the peaks. The models <inline-formula><mml:math id="mm181" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm182" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> generated nearly identical predictions in the first 24 h, but <inline-formula><mml:math id="mm183" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> stood out for the ability to predict subsequent peaks even if they were not identified by the sampling method.</p><p>On the other hand, a quantitative analysis of the results in <xref rid="pharmaceutics-16-01044-t006" ref-type="table">Table 6</xref> shows that increasing the number of model parameters does not necessarily imply an adjusted <inline-formula><mml:math id="mm184" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> value closer to 1. Models that required more parameters (<inline-formula><mml:math id="mm185" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm186" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="mm187" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>) had lower <inline-formula><mml:math id="mm188" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> values than models that required fewer parameters (<inline-formula><mml:math id="mm189" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm190" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>). However, the number of parameters increases if you increase the value of <inline-formula><mml:math id="mm191" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. In fact, model <inline-formula><mml:math id="mm192" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, which requires up to 14 parameters to fit a profile with four peaks, had the highest <inline-formula><mml:math id="mm193" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> value of all the models evaluated. As complex as it may seem, model <inline-formula><mml:math id="mm194" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, described by Equation (12), requires relatively few parameters to describe various peaks, which is reflected in the smallest <inline-formula><mml:math id="mm195" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of all the models evaluated.</p><p>It is important to mention that the greater the number of secondary peaks that you want to model, the greater the number of parameters. Increasing the number of parameters also implies increasing the number of samples; otherwise, the NLR could not be performed. The number of samples must be greater than or equal to the number of parameters to be used to characterize one or more peaks. <xref rid="pharmaceutics-16-01044-t008" ref-type="table">Table 8</xref> shows the number of parameters (and, therefore, minimum samples required) to characterize the peaks of a plasma profile with EHC. Depending on the number of peaks observed, you might choose to use more or fewer parameters for a given model.</p><p>Regarding the accuracy of the prediction <inline-formula><mml:math id="mm196" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>, it is interesting to note that even the classical model of extravascular administration (<inline-formula><mml:math id="mm197" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>) that is unable to capture secondary peaks has an accuracy in <inline-formula><mml:math id="mm198" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> estimation similar to some of the models that can capture secondary peaks. Previously, we presented an empirical model to capture the secondary peaks of the plasma profile of simvastatin [<xref rid="B38-pharmaceutics-16-01044" ref-type="bibr">38</xref>], which is equivalent to the model <inline-formula><mml:math id="mm199" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> of this work. Unlike our previous work, this time, the biexponential model <inline-formula><mml:math id="mm200" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> was better at estimating <inline-formula><mml:math id="mm201" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> than the model <inline-formula><mml:math id="mm202" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>. This suggests that model <inline-formula><mml:math id="mm203" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> might fit well with the plasma profiles of simvastatin but not with other drugs with different pharmacokinetic characteristics.</p><p>With respect to the model first proposed by Premaud et al. [<xref rid="B37-pharmaceutics-16-01044" ref-type="bibr">37</xref>] and that in this work, which is equivalent to the model <inline-formula><mml:math id="mm204" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, a couple of questions can be said. This model has undoubtedly been the most successful in practice, as it has demonstrated its superiority in the field of TDM over the fixed dose in the monitoring of mycophenonlate mofetil, a drug with a narrow therapeutic margin [<xref rid="B68-pharmaceutics-16-01044" ref-type="bibr">68</xref>]. Adaptations to it have even been proposed for the case of profiles with three peaks, which has allowed its usefulness to be further expanded [<xref rid="B39-pharmaceutics-16-01044" ref-type="bibr">39</xref>]. In this paper, we present the model in its general form to be able to model any number of peaks, Equation (9), and we also provide a formula for the exact calculation of <inline-formula><mml:math id="mm205" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> from its parameters, Equation (S3). However, in this work, there were models that presented a better performance; this was mainly because other models required a smaller number of parameters to model the same pharmacokinetic profile. In addition, on many occasions, the execution of the NLR was less intuitive for <inline-formula><mml:math id="mm206" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> compared to other models such as <inline-formula><mml:math id="mm207" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>3</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="mm208" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>, and <inline-formula><mml:math id="mm209" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>.</p></sec><sec id="sec4dot3-pharmaceutics-16-01044"><title>4.3. Estimation of AUC in Different Pharmacokinetic Scenarios</title><p>Once the superiority of model <inline-formula><mml:math id="mm210" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> had been demonstrated, we proceeded to evaluate under which conditions it could be more useful and in which it does not offer significant improvements compared to the trapezoidal method. As mentioned above, the <inline-formula><mml:math id="mm211" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> model overestimated <inline-formula><mml:math id="mm212" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> in scenarios <inline-formula><mml:math id="mm213" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="mm214" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>. This suggests that <inline-formula><mml:math id="mm215" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> predictions from model <inline-formula><mml:math id="mm216" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> are more likely to be inaccurate for drugs that are eliminated very quickly or those with two-compartment kinetics in which the drug remains for longer in the body. It is important to note that kinetic equilibrium is not reached instantaneously between compartments, and the addition of a peripheral compartment in scenario <inline-formula><mml:math id="mm217" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> makes it possible to take into account the presence of highly lipophilic drugs. Considering this, model <inline-formula><mml:math id="mm218" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> might have trouble estimating <inline-formula><mml:math id="mm219" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of highly lipophilic drugs.</p><p>An important aspect to highlight is that <inline-formula><mml:math id="mm220" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> calculation for each scenario using Equation (S6) was not significantly different from the one calculated by the trapezoidal method. These results suggest that, if possible, the selection of a meal-based sampling scheme is more important than the selection of a complex model that fits the data well but does not offer practical improvements beyond a good fit.</p><p>In the past, it has been argued that possibly the use of the trapezoidal method in drugs undergoing EHC could lead to an overestimation of <inline-formula><mml:math id="mm221" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. This assumption is based on the fact that the lack of resolution of the secondary peaks would lead to an overestimation of the actual area of these peaks, similar to approximating the area of a circle inscribed within a square from the area of that square. However, in this paper, we observed that, more often than not, the trapezoidal method estimates the real quite well, at least when there is an exhaustive sampling based on meals; see <xref rid="pharmaceutics-16-01044-f006" ref-type="fig">Figure 6</xref>.</p></sec><sec id="sec4dot4-pharmaceutics-16-01044"><title>4.4. Estimation of AUC under Different Sampling Schemes</title><p>The results suggest that it is more important to opt for a meal-based sampling method when secondary peaks are very pronounced due to a high degree of EHC than when peaks are very small due to a low degree of EHC. Even so, in practice, it would be worthwhile to opt for meal-based sampling whenever possible, as the contribution of the EHC process to the <inline-formula><mml:math id="mm222" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of some drugs can be highly variable. For example, the variability of EHC in mycophenolic acid ranges from 10 to 60% [<xref rid="B69-pharmaceutics-16-01044" ref-type="bibr">69</xref>].</p><p>It is important to note that in a comprehensive meal-based or conventional sampling, the <inline-formula><mml:math id="mm223" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> calculated by the trapezoidal method is very similar to that calculated by model <inline-formula><mml:math id="mm224" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula>; see <xref rid="pharmaceutics-16-01044-f007" ref-type="fig">Figure 7</xref>. This result suggests that when sufficiently large numbers of samples are available, as in the case of bioequivalence studies, the differences between each of the methods for calculating <inline-formula><mml:math id="mm225" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> are negligible. In these cases, opting for the trapezoidal method would be the most practical.</p><p>When sampling was limited, we found that increasing the number of samples does not necessarily lead to an improvement in the estimation of <inline-formula><mml:math id="mm226" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. True improvements in the estimation of <inline-formula><mml:math id="mm227" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> were observed between TDM2 to TDM3 and TDM4 to TDM5 schemes. A more in-depth analysis of <xref rid="pharmaceutics-16-01044-f008" ref-type="fig">Figure 8</xref> shows that the TDM1 and TDM2 samples allow the characterization of only two peaks, TDM3 and TDM4 three peaks and TDM5 four peaks of the plasma profile. The clear conclusion is that it is more important to increase the number of properly characterized peaks than to increase the number of samples.</p><p>It is important to note that in our study, the sampling times for TDM were not chosen arbitrarily but followed the rationality of meal-based sampling. From <xref rid="pharmaceutics-16-01044-f008" ref-type="fig">Figure 8</xref>, it is easy to see that the sampling times coincide almost exactly with the maximums and minimums of the plasma profile. These results suggest that in the TDM of drugs subject to EHC, it is essential to establish a meal schedule for the planning of sampling and that these are taken for a sufficiently long time to characterize several peaks. In this sense, our work supports the suggestions made by Lixuan et al., who studied the effect of mealtimes on <inline-formula><mml:math id="mm228" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of mycophenolic acid [<xref rid="B70-pharmaceutics-16-01044" ref-type="bibr">70</xref>].</p></sec><sec id="sec4dot5-pharmaceutics-16-01044"><title>4.5. Application of Model M5</title><p>Our study has the limitation that it does not have data from individual real-world profiles; we only had access to the average plasma profiles of some drugs published in other studies. Even so, we were able to adjust model <inline-formula><mml:math id="mm229" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> to all the profiles collected and obtained, in most cases, the estimates of <inline-formula><mml:math id="mm230" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> that were quite close to those reported in their respective articles. In the process, we obtained profiles with dynamics for which we cannot be sure that they approximate the real dynamics since several of these studies did not report or consider the mealtimes for sampling. The adjustment of the proposed model to these profiles is the first step to promote its application in data generated from real-world studies based on rational sampling.</p><p>It is clear that one of the deficiencies of model <inline-formula><mml:math id="mm231" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> is its inability to estimate the degree of EHC; however, as seen in <xref rid="pharmaceutics-16-01044-t007" ref-type="table">Table 7</xref>, this model estimates the <inline-formula><mml:math id="mm232" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> quite well. It is not easy to estimate experimentally the degree of EHC that a drug experiences, and there are few works that report this value. Due to the inability to perform an analysis of the fit of model <inline-formula><mml:math id="mm233" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> to the profiles of the drugs studied from these data, we opted to use the elimination half-life <inline-formula><mml:math id="mm234" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> to perform this analysis.</p><p>We previously pointed out that the M5 model had difficulties in adequately estimating the <inline-formula><mml:math id="mm235" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> in those scenarios that considered drugs with very long permanence in the body. In <xref rid="pharmaceutics-16-01044-t007" ref-type="table">Table 7</xref>, we find precisely that model <inline-formula><mml:math id="mm236" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> considerably overestimated the <inline-formula><mml:math id="mm237" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of meloxicam and amiodarone, which have a very high <inline-formula><mml:math id="mm238" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> (39.5 h and more than 25 days, respectively). At the other extreme, model <inline-formula><mml:math id="mm239" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> underestimated the <inline-formula><mml:math id="mm240" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> of ezetimibe although it does not have a particularly high <inline-formula><mml:math id="mm241" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> (between 13.8 and 15.1 h).</p><p>It should be clarified that although the empirical models were applied to data generated from simulations of the EHC process, in theory, they could be applied to any other profile that has multiple peaks caused by mechanisms other than the EHC. This would be possible since, being of an empirical nature, they do not need the determination of kinetic parameters of physiological or physicochemical basis. In this way, they could be applied to plasma profiles that show multiple peaks, such as those caused by pulsatile delivery systems [<xref rid="B71-pharmaceutics-16-01044" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-16-01044" ref-type="bibr">72</xref>] (examples of these commercially available pulsatile systems are Pulsincap<sup>&#174;</sup>, Ritalin<sup>&#174;</sup>, Pulsys<sup>&#174;</sup>) or those caused by physicochemical differences between different regions of the gastrointestinal tract. It has been suggested that differences in the pH of the gastrointestinal tract that ionize mycophenolic acid and not EHC could be responsible for the double-peak phenomenon observed in this drug [<xref rid="B73-pharmaceutics-16-01044" ref-type="bibr">73</xref>]. However, it would be inapplicable to vascular delivery drug profiles that exhibit multiple spikes regardless of the mechanism behind these spikes (e.g., fentanyl, sufentanil, propofol, and phenoperidine [<xref rid="B74-pharmaceutics-16-01044" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-16-01044" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceutics-16-01044" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-16-01044" ref-type="bibr">77</xref>]).</p><p>We highlight the feasibility of applying model <inline-formula><mml:math id="mm242" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> as a structural model in population pharmacokinetic models. Many structural models employed in population pharmacokinetic approaches have used physiological or mechanism-based concepts to describe the EHC [<xref rid="B78-pharmaceutics-16-01044" ref-type="bibr">78</xref>]. An example of the success of this type of model contains forty-five structural parameters and simultaneously describes the extent and time course of EHC in rats, dogs, and humans for fimasartan [<xref rid="B79-pharmaceutics-16-01044" ref-type="bibr">79</xref>]. However, empirical models with fewer parameters might present advantages as structural models. The most recent example is the non-linear mixed effect (NLME) approach based on stochastic approximation expectation&#8211;maximization for the double gamma distribution model [<xref rid="B80-pharmaceutics-16-01044" ref-type="bibr">80</xref>].</p><p>Our model is unable to predict the effect on the pharmacokinetic profile of variables such as age, gender, body weight, pathological states, etc. In this sense, the inclusion of covariates in our model for the development of further population pharmacokinetic models would allow us to limit its application to specific clinical environments in the same way that has been done for the model proposed by Premaud et al. [<xref rid="B37-pharmaceutics-16-01044" ref-type="bibr">37</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-16-01044"><title>5. Conclusions</title><p>In this study, we conducted simulations to assess the impact of EHC on <inline-formula><mml:math id="mm243" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> in various scenarios. Our findings indicate that modulating biliary transport can effectively increase <inline-formula><mml:math id="mm244" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>. We evaluated five empirical models for characterizing EHC peaks, identifying model <inline-formula><mml:math id="mm245" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> as the most efficient due to its simplicity, accurate <inline-formula><mml:math id="mm246" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> estimates, and ability to predict peaks beyond sampling times. While model <inline-formula><mml:math id="mm247" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>M</mml:mi><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math></inline-formula> performed well in most scenarios, it struggled with drugs exhibiting rapid renal elimination or bicompartmental kinetics.</p><p>Evaluation of different sampling schemes revealed that our proposed model did not consistently outperform the trapezoidal method, particularly with extensive sampling. However, limited sampling for TDM benefited from our model&#8217;s ability to characterize peaks, yielding superior <inline-formula><mml:math id="mm248" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula> estimates compared to the trapezoidal method. In conclusion, this study underscored the importance of implementing meal-based sampling schemes and laid the groundwork for applying empirical models in real-world studies of drugs undergoing EHC.</p></sec></body><back><ack><title>Acknowledgments</title><p>The graphical abstract was created using &#8220;Server Medical Art. Servier Medical Art by Servier&#8221;, licensed under a Creative Commons Attribution 3.0 Unported License.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-16-01044"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics16081044/s1">https://www.mdpi.com/article/10.3390/pharmaceutics16081044/s1</uri>, Supplementary Data S1: Equations for AUC calculation; Supplementary Data S2: Source script; Supplementary Data S3: Simulations of pharmacokinetic scenarios; Supplementary Data S4: Fit of model M5 to selected plasma profiles; Supplementary Data S5: Linearity of compartmental model.</p><supplementary-material id="pharmaceutics-16-01044-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-16-01044-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, M.A. and M.A.T.; methodology, M.A.T.; formal analysis, M.A.T.; data curation, E.G.M. and J.d.J.R.; writing&#8212;original draft preparation, M.A.T.; writing&#8212;review and editing, S.D.; visualization, J.d.J.R.; supervision, M.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available upon request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Authors were employed by the company CEDOPEC. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-16-01044"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>L.</given-names></name></person-group><article-title>Drug Enterohepatic Circulation and Disposition: Constituents of Systems Pharmacokinetics</article-title><source>Drug Discov. Today</source><year>2014</year><volume>19</volume><fpage>326</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2013.11.020</pub-id><pub-id pub-id-type="pmid">24295642</pub-id></element-citation></ref><ref id="B2-pharmaceutics-16-01044"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jetter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kullak-Ublick</surname><given-names>G.A.</given-names></name></person-group><article-title>Drugs and Hepatic Transporters: A Review</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>154</volume><fpage>104234</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2019.04.018</pub-id><pub-id pub-id-type="pmid">31004787</pub-id></element-citation></ref><ref id="B3-pharmaceutics-16-01044"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durn&#237;k</surname><given-names>R.</given-names></name><name name-style="western"><surname>&#352;indlerov&#225;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Babica</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jur&#269;ek</surname><given-names>O.</given-names></name></person-group><article-title>Bile Acids Transporters of Enterohepatic Circulation for Targeted Drug Delivery</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>2961</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27092961</pub-id><pub-id pub-id-type="pmid">35566302</pub-id><pub-id pub-id-type="pmcid">PMC9103499</pub-id></element-citation></ref><ref id="B4-pharmaceutics-16-01044"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guiastrennec</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sonne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rehfeld</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alsk&#228;r</surname><given-names>O.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vilsb&#248;ll</surname><given-names>T.</given-names></name><name name-style="western"><surname>Knop</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake</article-title><source>CPT Pharmacomet. Syst. Pharmacol.</source><year>2016</year><volume>5</volume><fpage>692</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1002/psp4.12152</pub-id><pub-id pub-id-type="pmcid">PMC5192972</pub-id><pub-id pub-id-type="pmid">28028939</pub-id></element-citation></ref><ref id="B5-pharmaceutics-16-01044"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivy</surname><given-names>A.C.</given-names></name></person-group><article-title>A Hormone Mechanism for Gall-Bladder Contraction &amp; Evacuation</article-title><source>Am. J. Surg.</source><year>1929</year><volume>7</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/S0002-9610(29)90551-1</pub-id></element-citation></ref><ref id="B6-pharmaceutics-16-01044"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaffer</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>McOrmond</surname><given-names>P.</given-names></name><name name-style="western"><surname>Duggan</surname><given-names>H.</given-names></name></person-group><article-title>Quantitative Cholescintigraphy: Assessment of Gallbladder Filling and Emptying and Duodenogastric Reflux</article-title><source>Gastroenterology</source><year>1980</year><volume>79</volume><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(80)90448-5</pub-id><pub-id pub-id-type="pmid">7419014</pub-id></element-citation></ref><ref id="B7-pharmaceutics-16-01044"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portincasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moschetta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giampaolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palasciano</surname><given-names>G.</given-names></name></person-group><article-title>Diffuse Gastrointestinal Dysmotility by Ultrasonography, Manometry and Breath Tests in Colonic Inertia</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2000</year><volume>4</volume><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">11550758</pub-id></element-citation></ref><ref id="B8-pharmaceutics-16-01044"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>R.H.</given-names></name></person-group><article-title>Gall Bladder Emptying Patterns in Response to a Normal Meal in Healthy Subjects and Patients with Gall Stones: Ultrasound Study</article-title><source>Gut</source><year>1991</year><volume>32</volume><fpage>1406</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1136/gut.32.11.1406</pub-id><pub-id pub-id-type="pmid">1752478</pub-id><pub-id pub-id-type="pmcid">PMC1379178</pub-id></element-citation></ref><ref id="B9-pharmaceutics-16-01044"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>R.C.</given-names></name></person-group><article-title>Modeling Enterohepatic Circulation</article-title><source>Curr. Pharmacol. Rep.</source><year>2017</year><volume>3</volume><fpage>301</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1007/s40495-017-0096-z</pub-id></element-citation></ref><ref id="B10-pharmaceutics-16-01044"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Gibaldi</surname><given-names>M.</given-names></name></person-group><article-title>Influence of Cholestasis on Drug Elimination: Pharmacokinetics</article-title><source>J. Pharm. Sci.</source><year>1976</year><volume>65</volume><fpage>1346</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1002/jps.2600650921</pub-id><pub-id pub-id-type="pmid">966151</pub-id></element-citation></ref><ref id="B11-pharmaceutics-16-01044"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steimer</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Plusquellec</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guillaume</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boisvieux</surname><given-names>J.-F.</given-names></name></person-group><article-title>A Time-Lag Model for Pharmacokinetics of Drugs Subject to Enterohepatic Circulation</article-title><source>J. Pharm. Sci.</source><year>1982</year><volume>71</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1002/jps.2600710308</pub-id><pub-id pub-id-type="pmid">7069584</pub-id></element-citation></ref><ref id="B12-pharmaceutics-16-01044"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colburn</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Hirom</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Milburn</surname><given-names>P.</given-names></name></person-group><article-title>A Pharmacokinetic Model for Enterohepatic Recirculation in the Rat: Phenolphthalein, a Model Drug</article-title><source>Drug Metab. Dispos.</source><year>1979</year><volume>7</volume><fpage>100</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">38070</pub-id></element-citation></ref><ref id="B13-pharmaceutics-16-01044"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colburn</surname><given-names>W.A.</given-names></name></person-group><article-title>Pharmacokinetic and Biopharmaceutic Parameters During Enterohepatic Circulation of Drugs</article-title><source>J. Pharm. Sci.</source><year>1982</year><volume>71</volume><fpage>131</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1002/jps.2600710139</pub-id><pub-id pub-id-type="pmid">7057372</pub-id></element-citation></ref><ref id="B14-pharmaceutics-16-01044"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name></person-group><article-title>Pharmacokinetics and Bioavailability of Cimetidine in Humans</article-title><source>J. Pharm. Sci.</source><year>1980</year><volume>69</volume><fpage>394</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1002/jps.2600690408</pub-id><pub-id pub-id-type="pmid">7373532</pub-id></element-citation></ref><ref id="B15-pharmaceutics-16-01044"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name></person-group><article-title>Pharmacokinetics of Doxycycline Reabsorption</article-title><source>J. Pharm. Sci.</source><year>1980</year><volume>69</volume><fpage>204</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1002/jps.2600690224</pub-id><pub-id pub-id-type="pmid">7359326</pub-id></element-citation></ref><ref id="B16-pharmaceutics-16-01044"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name></person-group><article-title>Pharmacokinetics and Bioavailability of Ranitidine in Humans</article-title><source>J. Pharm. Sci.</source><year>1984</year><volume>73</volume><fpage>1376</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1002/jps.2600731013</pub-id><pub-id pub-id-type="pmid">6094785</pub-id></element-citation></ref><ref id="B17-pharmaceutics-16-01044"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ide</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I.</given-names></name></person-group><article-title>Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined with Pharmacogenomic Information on SLCO1B1 and ABCC2 Polymorphisms</article-title><source>J. Clin. Pharmacol.</source><year>2009</year><volume>49</volume><fpage>1309</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1177/0091270009341960</pub-id><pub-id pub-id-type="pmid">19776292</pub-id></element-citation></ref><ref id="B18-pharmaceutics-16-01044"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Funaki</surname><given-names>T.</given-names></name></person-group><article-title>Enterohepatic Circulation Model for Population Pharmacokinetic Analysis</article-title><source>J. Pharm. Pharmacol.</source><year>2010</year><volume>51</volume><fpage>1143</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1211/0022357991776831</pub-id><pub-id pub-id-type="pmid">10579685</pub-id></element-citation></ref><ref id="B19-pharmaceutics-16-01044"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strandg&#229;rden</surname><given-names>K.</given-names></name><name name-style="western"><surname>H&#246;glund</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gr&#246;nquist</surname><given-names>L.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gunnarsson</surname><given-names>P.O.</given-names></name></person-group><article-title>Absorption and Disposition Including Enterohepatic Circulation of (14C) Roquinimex after Oral Administration to Healthy Volunteers</article-title><source>Biopharm. Drug Dispos.</source><year>2000</year><volume>21</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1099-081X(200003)21:2&amp;#x0003c;53::AID-BDD214&amp;#x0003e;3.0.CO;2-F</pub-id><pub-id pub-id-type="pmid">11100907</pub-id></element-citation></ref><ref id="B20-pharmaceutics-16-01044"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Panetta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Innocenti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ratain</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacogenetic Pathway Analysis of Irinotecan</article-title><source>Clin. Pharmacol. Ther.</source><year>2008</year><volume>84</volume><fpage>393</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/clpt.2008.63</pub-id><pub-id pub-id-type="pmid">18418374</pub-id><pub-id pub-id-type="pmcid">PMC2759399</pub-id></element-citation></ref><ref id="B21-pharmaceutics-16-01044"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name></person-group><article-title>Population Pharmacokinetic Modelling for Enterohepatic Circulation of Mycophenolic Acid in Healthy Chinese and the Influence of Polymorphisms in UGT1A9</article-title><source>Br. J. Clin. Pharmacol.</source><year>2008</year><volume>65</volume><fpage>893</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2008.03109.x</pub-id><pub-id pub-id-type="pmid">18279479</pub-id><pub-id pub-id-type="pmcid">PMC2485216</pub-id></element-citation></ref><ref id="B22-pharmaceutics-16-01044"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sam</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Akhlaghi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rosenbaum</surname><given-names>S.E.</given-names></name></person-group><article-title>Population Pharmacokinetics of Mycophenolic Acid and Its 2 Glucuronidated Metabolites in Kidney Transplant Recipients</article-title><source>J. Clin. Pharmacol.</source><year>2009</year><volume>49</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1177/0091270008329558</pub-id><pub-id pub-id-type="pmid">19179297</pub-id></element-citation></ref><ref id="B23-pharmaceutics-16-01044"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Winter</surname><given-names>B.C.M.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sombogaard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mathot</surname><given-names>R.A.A.</given-names></name></person-group><article-title>Pharmacokinetic Role of Protein Binding of Mycophenolic Acid and Its Glucuronide Metabolite in Renal Transplant Recipients</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2009</year><volume>36</volume><fpage>541</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1007/s10928-009-9136-6</pub-id><pub-id pub-id-type="pmid">19904584</pub-id><pub-id pub-id-type="pmcid">PMC2784070</pub-id></element-citation></ref><ref id="B24-pharmaceutics-16-01044"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yau</surname><given-names>W.-P.</given-names></name><name name-style="western"><surname>Vathsala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>H.-X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.</given-names></name></person-group><article-title>Mechanism-Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients</article-title><source>J. Clin. Pharmacol.</source><year>2009</year><volume>49</volume><fpage>684</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1177/0091270009332813</pub-id><pub-id pub-id-type="pmid">19386625</pub-id></element-citation></ref><ref id="B25-pharmaceutics-16-01044"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berg</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Mandrekar</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>K.L.A.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ames</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Boring</surname><given-names>D.</given-names></name><name name-style="western"><surname>Limburg</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>J.M.</given-names></name></person-group><article-title>Population Pharmacokinetic Model for Cancer Chemoprevention with Sulindac in Healthy Subjects</article-title><source>J. Clin. Pharmacol.</source><year>2013</year><volume>53</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1002/jcph.26</pub-id><pub-id pub-id-type="pmid">23436338</pub-id><pub-id pub-id-type="pmcid">PMC4120995</pub-id></element-citation></ref><ref id="B26-pharmaceutics-16-01044"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shepard</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Reuning</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Aarons</surname><given-names>L.J.</given-names></name></person-group><article-title>Estimation of Area under the Curve for Drugs Subject to Enterohepatic Cycling</article-title><source>J. Pharmacokinet. Biopharm.</source><year>1985</year><volume>13</volume><fpage>589</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1007/BF01058903</pub-id><pub-id pub-id-type="pmid">3834073</pub-id></element-citation></ref><ref id="B27-pharmaceutics-16-01044"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>L.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Dahut</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Kohn</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Kummar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mould</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Giaccone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yarchoan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Venitz</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumours</article-title><source>Br. J. Clin. Pharmacol.</source><year>2011</year><volume>72</volume><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03963.x</pub-id><pub-id pub-id-type="pmid">21392074</pub-id><pub-id pub-id-type="pmcid">PMC3162659</pub-id></element-citation></ref><ref id="B28-pharmaceutics-16-01044"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huntjens</surname><given-names>D.R.H.</given-names></name><name name-style="western"><surname>Strougo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Metcalf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Summerfield</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spalding</surname><given-names>D.J.M.</given-names></name><name name-style="western"><surname>Danhof</surname><given-names>M.</given-names></name><name name-style="western"><surname>Della Pasqua</surname><given-names>O.</given-names></name></person-group><article-title>Population Pharmacokinetic Modelling of the Enterohepatic Recirculation of Diclofenac and Rofecoxib in Rats</article-title><source>Br. J. Pharmacol.</source><year>2008</year><volume>153</volume><fpage>1072</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707643</pub-id><pub-id pub-id-type="pmid">18193075</pub-id><pub-id pub-id-type="pmcid">PMC2267282</pub-id></element-citation></ref><ref id="B29-pharmaceutics-16-01044"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wajima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oguma</surname><given-names>T.</given-names></name></person-group><article-title>A Pharmacokinetic Model for Analysis of Drug Disposition Profiles Undergoing Enterohepatic Circulation</article-title><source>J. Pharm. Pharmacol.</source><year>2010</year><volume>54</volume><fpage>929</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1211/002235702760089045</pub-id><pub-id pub-id-type="pmid">12162711</pub-id></element-citation></ref><ref id="B30-pharmaceutics-16-01044"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edginton</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Vasilyeva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Panetta</surname><given-names>J.C.</given-names></name></person-group><article-title>Sorafenib Metabolism, Transport, and Enterohepatic Recycling: Physiologically Based Modeling and Simulation in Mice</article-title><source>Cancer Chemother. Pharmacol.</source><year>2016</year><volume>77</volume><fpage>1039</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3018-6</pub-id><pub-id pub-id-type="pmid">27053087</pub-id><pub-id pub-id-type="pmcid">PMC4846505</pub-id></element-citation></ref><ref id="B31-pharmaceutics-16-01044"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbiati</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Manca</surname><given-names>D.</given-names></name></person-group><article-title>Enterohepatic Circulation Effect in Physiologically Based Pharmacokinetic Models: The Sorafenib Case</article-title><source>Ind. Eng. Chem. Res.</source><year>2017</year><volume>56</volume><fpage>3156</fpage><lpage>3166</lpage><pub-id pub-id-type="doi">10.1021/acs.iecr.6b03686</pub-id></element-citation></ref><ref id="B32-pharmaceutics-16-01044"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voronova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sokolov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Al-Khaifi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Straniero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peskov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Helmlinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rudling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angelin</surname><given-names>B.</given-names></name></person-group><article-title>A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings</article-title><source>Cell Mol. Gastroenterol. Hepatol.</source><year>2020</year><volume>10</volume><fpage>149</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2020.02.005</pub-id><pub-id pub-id-type="pmid">32112828</pub-id><pub-id pub-id-type="pmcid">PMC7240226</pub-id></element-citation></ref><ref id="B33-pharmaceutics-16-01044"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Scherf-Clavel</surname><given-names>O.</given-names></name></person-group><article-title>Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug&#8211;Drug Interaction with Rifampin and Liver Impairment</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>778</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13060778</pub-id><pub-id pub-id-type="pmid">34067429</pub-id><pub-id pub-id-type="pmcid">PMC8224782</pub-id></element-citation></ref><ref id="B34-pharmaceutics-16-01044"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Conner</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name></person-group><article-title>Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: An Overview</article-title><source>Curr. Pharmacol. Rep.</source><year>2020</year><volume>6</volume><fpage>71</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1007/s40495-020-00212-x</pub-id><pub-id pub-id-type="pmid">32399388</pub-id><pub-id pub-id-type="pmcid">PMC7214223</pub-id></element-citation></ref><ref id="B35-pharmaceutics-16-01044"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Worley</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>J.W.</given-names></name></person-group><article-title>Challenges Associated with Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making</article-title><source>Toxicol. Sci.</source><year>2018</year><volume>162</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfy010</pub-id><pub-id pub-id-type="pmid">29385573</pub-id><pub-id pub-id-type="pmcid">PMC6084449</pub-id></element-citation></ref><ref id="B36-pharmaceutics-16-01044"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>M.</given-names></name></person-group><article-title>Empirical Models for Fitting of Oral Concentration Time Curves with and without an Intravenous Reference</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2017</year><volume>44</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1007/s10928-017-9507-3</pub-id><pub-id pub-id-type="pmid">28150181</pub-id></element-citation></ref><ref id="B37-pharmaceutics-16-01044"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pr&#233;maud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Debord</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le Meur</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Toupance</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lebranchu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hoizey</surname><given-names>G.</given-names></name><name name-style="western"><surname>Le Guellec</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name></person-group><article-title>A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in de Novo Renal Transplant Recipients given Oral Mycophenolate Mofetil</article-title><source>Clin. Pharmacokinet.</source><year>2005</year><volume>44</volume><fpage>837</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544080-00005</pub-id><pub-id pub-id-type="pmid">16029068</pub-id></element-citation></ref><ref id="B38-pharmaceutics-16-01044"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alp&#237;zar-Salazar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alejandro Trejo-Rangel</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Jes&#250;s Res&#233;ndiz-Rojas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frydman</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Ramos-Mundo</surname><given-names>C.</given-names></name></person-group><article-title>A Modified Compartmental Pharmacokinetic Model of Enterohepatic Circulation for Simvastatin in Healthy Mexican Subjects. A Pilot Study</article-title><source>J. Pharm. Pharmacol. Res.</source><year>2020</year><volume>4</volume><pub-id pub-id-type="doi">10.26502/fjppr.036</pub-id></element-citation></ref><ref id="B39-pharmaceutics-16-01044"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahr</surname><given-names>N.</given-names></name><name name-style="western"><surname>Amoura</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Debord</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hulot</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Saint-Marcoux</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Piette</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lechat</surname><given-names>P.</given-names></name></person-group><article-title>Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies</article-title><source>Clin. Pharmacokinet.</source><year>2008</year><volume>47</volume><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.2165/00003088-200847040-00005</pub-id><pub-id pub-id-type="pmid">18336056</pub-id></element-citation></ref><ref id="B40-pharmaceutics-16-01044"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibarra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Troc&#243;niz</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Fagiolino</surname><given-names>P.</given-names></name></person-group><article-title>Enteric Reabsorption Processes and Their Impact on Drug Pharmacokinetics</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>5794</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-85174-w</pub-id><pub-id pub-id-type="pmid">33707635</pub-id><pub-id pub-id-type="pmcid">PMC7952424</pub-id></element-citation></ref><ref id="B41-pharmaceutics-16-01044"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Le Meur</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Oellerich</surname><given-names>M.</given-names></name><name name-style="western"><surname>DeNofrio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holt</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kuypers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Meiser</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation</article-title><source>Ther. Drug Monit.</source><year>2006</year><volume>28</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1097/01.ftd.0000199358.80013.bd</pub-id><pub-id pub-id-type="pmid">16628123</pub-id></element-citation></ref><ref id="B42-pharmaceutics-16-01044"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sousa Lobo</surname><given-names>J.M.</given-names></name></person-group><article-title>Modeling and Comparison of Dissolution Profiles</article-title><source>Eur. J. Pharm. Sci.</source><year>2001</year><volume>13</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/S0928-0987(01)00095-1</pub-id><pub-id pub-id-type="pmid">11297896</pub-id></element-citation></ref><ref id="B43-pharmaceutics-16-01044"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drevon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fursa</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Malcolm</surname><given-names>A.L.</given-names></name></person-group><article-title>Intercoder Reliability and Validity of WebPlotDigitizer in Extracting Graphed Data</article-title><source>Behav. Modif.</source><year>2017</year><volume>41</volume><fpage>323</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1177/0145445516673998</pub-id><pub-id pub-id-type="pmid">27760807</pub-id></element-citation></ref><ref id="B44-pharmaceutics-16-01044"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>C.-I.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-Y.</given-names></name></person-group><article-title>Effects of CYP2C9*1/*13 on the Pharmacokinetics and Pharmacodynamics of Meloxicam</article-title><source>Br. J. Clin. Pharmacol.</source><year>2011</year><volume>71</volume><fpage>550</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2010.03853.x</pub-id><pub-id pub-id-type="pmid">21395648</pub-id><pub-id pub-id-type="pmcid">PMC3080643</pub-id></element-citation></ref><ref id="B45-pharmaceutics-16-01044"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ajavon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lettieri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berse</surname><given-names>M.</given-names></name></person-group><article-title>No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects</article-title><source>Thyroid</source><year>2017</year><volume>27</volume><fpage>1118</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1089/thy.2017.0085</pub-id><pub-id pub-id-type="pmid">28741453</pub-id><pub-id pub-id-type="pmcid">PMC5646750</pub-id></element-citation></ref><ref id="B46-pharmaceutics-16-01044"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ilha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nucci</surname><given-names>G.</given-names></name></person-group><article-title>Comparative Bioavailability Study with Two Amiodarone Tablet Formulations Administered with and without Food in Healthy Subjects</article-title><source>Arzneimittelforschung</source><year>2011</year><volume>57</volume><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1296653</pub-id><pub-id pub-id-type="pmid">17966757</pub-id></element-citation></ref><ref id="B47-pharmaceutics-16-01044"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danafar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hamidi</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacokinetics and Bioequivalence of Methotrexate in Human Plasma Studied by Liquid Chromatography-Mass Spectrometry (LC-MS)</article-title><source>Jundishapur J. Nat. Pharm. Prod.</source><year>2016</year><volume>11</volume><pub-id pub-id-type="doi">10.17795/jjnpp-36758</pub-id></element-citation></ref><ref id="B48-pharmaceutics-16-01044"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ducharme</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Warbasse</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.J.</given-names></name></person-group><article-title>Disposition of Intravenous and Oral Cyclosporine after Administration with Grapefruit Juice*</article-title><source>Clin. Pharmacol. Ther.</source><year>1995</year><volume>57</volume><fpage>485</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/0009-9236(95)90032-2</pub-id><pub-id pub-id-type="pmid">7768070</pub-id></element-citation></ref><ref id="B49-pharmaceutics-16-01044"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>J.</given-names></name></person-group><article-title>Comparative Pharmacokinetic Profiles of a Novel Low-Dose Micronized-Isotretinoin 32 Mg Formulation and Lidose-Isotretinoin 40 Mg in Fed and Fasted Conditions: Two Open-Label, Randomized, Crossover Studies in Healthy Adult Participants</article-title><source>Acta Derm. Venereol.</source><year>2019</year><volume>100</volume><fpage>adv00049</fpage><pub-id pub-id-type="doi">10.2340/00015555-3381</pub-id><pub-id pub-id-type="pmcid">PMC9128969</pub-id><pub-id pub-id-type="pmid">31774544</pub-id></element-citation></ref><ref id="B50-pharmaceutics-16-01044"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Shrivastav</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>M.</given-names></name></person-group><article-title>Liquid Chromatography Tandem Mass Spectrometry Method for Determination of Febuxostat in Human Plasma to Support a Bioequivalence Study</article-title><source>J. Adv. Pharm. Sci. Technol.</source><year>2013</year><volume>1</volume><fpage>37</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.14302/issn.2328-0182.japst-12-173</pub-id></element-citation></ref><ref id="B51-pharmaceutics-16-01044"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeGregorio</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Wurz</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Taras</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Erkkola</surname><given-names>R.U.</given-names></name><name name-style="western"><surname>Halonen</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Huupponen</surname><given-names>R.K.</given-names></name></person-group><article-title>Pharmacokinetics of (Deaminohydroxy)Toremifene in Humans: A New, Selective Estrogen-Receptor Modulator</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2000</year><volume>56</volume><fpage>469</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1007/s002280000176</pub-id><pub-id pub-id-type="pmid">11049009</pub-id></element-citation></ref><ref id="B52-pharmaceutics-16-01044"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pati&#241;o-Rodr&#237;guez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Torres-Roque</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Delgado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Escobedo-Moratilla</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;rez-Urizar</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetic Non-Interaction Analysis in a Fixed-Dose Formulation in Combination of Atorvastatin and Ezetimibe</article-title><source>Front. Pharmacol.</source><year>2014</year><volume>5</volume><elocation-id>261</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2014.00261</pub-id><pub-id pub-id-type="pmid">25505887</pub-id><pub-id pub-id-type="pmcid">PMC4245888</pub-id></element-citation></ref><ref id="B53-pharmaceutics-16-01044"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kunhihitlu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Costantini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esquivel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Roush</surname><given-names>J.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>T.W.K.</given-names></name></person-group><article-title>Pharmacokinetic Bioequivalence Crossover Study of Branded Generic and Innovator Formulations of the Cholesterol Lowering Agent Ezetimibe</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2014</year><volume>3</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1002/cpdd.80</pub-id><pub-id pub-id-type="pmid">27128615</pub-id></element-citation></ref><ref id="B54-pharmaceutics-16-01044"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olugemo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Solorio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Young</surname><given-names>C.L.</given-names></name></person-group><article-title>Pharmacokinetics and Safety of Low-Dose Submicron Indomethacin 20 and 40 Mg Compared with Indomethacin 50 Mg</article-title><source>Postgrad. Med.</source><year>2015</year><volume>127</volume><fpage>223</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1080/00325481.2015.1000231</pub-id><pub-id pub-id-type="pmid">25639879</pub-id></element-citation></ref><ref id="B55-pharmaceutics-16-01044"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limopasmanee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chansakaow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rojanasthien</surname><given-names>N.</given-names></name><name name-style="western"><surname>Manorot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sangdee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teekachunhatean</surname><given-names>S.</given-names></name></person-group><article-title>Effects of the Chinese Herbal Formulation (Liu Wei Di Huang Wan) on the Pharmacokinetics of Isoflavones in Postmenopausal Women</article-title><source>Biomed. Res. Int.</source><year>2015</year><volume>2015</volume><elocation-id>902702</elocation-id><pub-id pub-id-type="doi">10.1155/2015/902702</pub-id><pub-id pub-id-type="pmid">26146635</pub-id><pub-id pub-id-type="pmcid">PMC4471402</pub-id></element-citation></ref><ref id="B56-pharmaceutics-16-01044"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>I.-J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacokinetic Comparison between Fixed-Dose Combination of Fimasartan/Amlodipine 60/10 Mg and the Corresponding Loose Combination through Partial Replicated Crossover Study in Healthy Subjects</article-title><source>Transl. Clin. Pharmacol.</source><year>2019</year><volume>27</volume><fpage>134</fpage><pub-id pub-id-type="doi">10.12793/tcp.2019.27.4.134</pub-id><pub-id pub-id-type="pmid">32095481</pub-id><pub-id pub-id-type="pmcid">PMC7032963</pub-id></element-citation></ref><ref id="B57-pharmaceutics-16-01044"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brundage</surname><given-names>R.C.</given-names></name></person-group><article-title>A Gallbladder-Based Enterohepatic Circulation Model for Pharmacokinetic Studies</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>2019</year><volume>44</volume><fpage>493</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1007/s13318-018-0535-1</pub-id><pub-id pub-id-type="pmid">30488336</pub-id></element-citation></ref><ref id="B58-pharmaceutics-16-01044"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandelman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>B.</given-names></name><name name-style="western"><surname>LaBadie</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Crownover</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bergstrom</surname><given-names>T.</given-names></name></person-group><article-title>Analytes of Interest and Choice of Dose: Two Important Considerations in the Design of Bioequivalence Studies with Atorvastatin</article-title><source>J. Bioequivalence Bioavailab.</source><year>2011</year><volume>3</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.4172/jbb.1000060</pub-id></element-citation></ref><ref id="B59-pharmaceutics-16-01044"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granger</surname><given-names>D.K.</given-names></name></person-group><article-title>Enteric-Coated Mycophenolate Sodium: Results of Two Pivotal Global Multicenter Trials</article-title><source>Transplant. Proc.</source><year>2001</year><volume>33</volume><fpage>3241</fpage><lpage>3244</lpage><pub-id pub-id-type="doi">10.1016/S0041-1345(01)02378-8</pub-id><pub-id pub-id-type="pmid">11750389</pub-id></element-citation></ref><ref id="B60-pharmaceutics-16-01044"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakiya</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hanano</surname><given-names>M.</given-names></name></person-group><article-title>Biliary Excretion and Enterohepatic Cycling of Glycyrrhizin in Rats</article-title><source>J. Pharm. Sci.</source><year>1986</year><volume>75</volume><fpage>672</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1002/jps.2600750711</pub-id><pub-id pub-id-type="pmid">3761168</pub-id></element-citation></ref><ref id="B61-pharmaceutics-16-01044"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kari</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D.</given-names></name><name name-style="western"><surname>Emary</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Adelsberger</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetic Modeling for Enterohepatic Recirculation in Rhesus Monkey</article-title><source>Eur. J. Pharm. Sci.</source><year>2005</year><volume>26</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2005.05.010</pub-id><pub-id pub-id-type="pmid">16085400</pub-id></element-citation></ref><ref id="B62-pharmaceutics-16-01044"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.-B.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.-S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.-G.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Z.-L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.-J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Ciprofloxacin Blocked Enterohepatic Circulation of Diclofenac and Alleviated NSAID-Induced Enteropathy in Rats Partly by Inhibiting Intestinal &#946;-Glucuronidase Activity</article-title><source>Acta Pharmacol. Sin.</source><year>2016</year><volume>37</volume><fpage>1002</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/aps.2016.54</pub-id><pub-id pub-id-type="pmid">27180979</pub-id><pub-id pub-id-type="pmcid">PMC4933763</pub-id></element-citation></ref><ref id="B63-pharmaceutics-16-01044"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meaney</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Sudchada</surname><given-names>P.</given-names></name><name name-style="western"><surname>Consiglio</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Wilding</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Venuto</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Tornatore</surname><given-names>K.M.</given-names></name></person-group><article-title>Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant</article-title><source>J. Clin. Pharmacol.</source><year>2019</year><volume>59</volume><fpage>1351</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1002/jcph.1428</pub-id><pub-id pub-id-type="pmid">31062373</pub-id><pub-id pub-id-type="pmcid">PMC7375007</pub-id></element-citation></ref><ref id="B64-pharmaceutics-16-01044"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shepard</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Reuning</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Aarons</surname><given-names>L.J.</given-names></name></person-group><article-title>Interpretation of Area Under the Curve Measurements for Drugs Subject to Enterohepatic Cycling</article-title><source>J. Pharm. Sci.</source><year>1985</year><volume>74</volume><fpage>227</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1002/jps.2600740228</pub-id><pub-id pub-id-type="pmid">3989699</pub-id></element-citation></ref><ref id="B65-pharmaceutics-16-01044"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scarfia</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Clementi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Granata</surname><given-names>A.</given-names></name></person-group><article-title>Rhabdomyolysis and Acute Kidney Injury Secondary to Interaction between Simvastatin and Cyclosporine</article-title><source>Ren. Fail.</source><year>2013</year><volume>35</volume><fpage>1056</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.3109/0886022X.2013.810540</pub-id><pub-id pub-id-type="pmid">23859539</pub-id></element-citation></ref><ref id="B66-pharmaceutics-16-01044"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keitel</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nies</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Brom</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hummel-Eisenbeiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spring</surname><given-names>H.</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>D.</given-names></name></person-group><article-title>A Common Dubin-Johnson Syndrome Mutation Impairs Protein Maturation and Transport Activity of MRP2 (ABCC2)</article-title><source>Am. J. Physiol. -Gastrointest. Liver Physiol.</source><year>2003</year><volume>284</volume><fpage>G165</fpage><lpage>G174</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00362.2002</pub-id><pub-id pub-id-type="pmid">12388192</pub-id></element-citation></ref><ref id="B67-pharmaceutics-16-01044"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>Effects of Cyclosporin A and Itraconazole on the Pharmacokinetics of Atorvastatin in Rats</article-title><source>Acta Pharmacol. Sin.</source><year>2008</year><volume>29</volume><fpage>1247</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1111/j.1745-7254.2008.00858.x</pub-id><pub-id pub-id-type="pmid">18817631</pub-id></element-citation></ref><ref id="B68-pharmaceutics-16-01044"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Meur</surname><given-names>Y.</given-names></name><name name-style="western"><surname>B&#252;chler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thierry</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caillard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Villemain</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lavaud</surname><given-names>S.</given-names></name><name name-style="western"><surname>Etienne</surname><given-names>I.</given-names></name><name name-style="western"><surname>Westeel</surname><given-names>P.-F.</given-names></name><name name-style="western"><surname>Hurault de Ligny</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rostaing</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes after Renal Transplantation</article-title><source>Am. J. Transpl.</source><year>2007</year><volume>7</volume><fpage>2496</fpage><lpage>2503</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2007.01983.x</pub-id><pub-id pub-id-type="pmid">17908276</pub-id></element-citation></ref><ref id="B69-pharmaceutics-16-01044"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullingham</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>B.R.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Mycophenolate Mofetil</article-title><source>Clin. Pharmacokinet.</source><year>1998</year><volume>34</volume><fpage>429</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.2165/00003088-199834060-00002</pub-id><pub-id pub-id-type="pmid">9646007</pub-id></element-citation></ref><ref id="B70-pharmaceutics-16-01044"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>M.</given-names></name></person-group><article-title>Effect of Meal Timings and Meal Content on the AUC0-12h of Mycophenolic Acid: A Simulation Study</article-title><source>Clin. Pharmacol. Drug Dev.</source><year>2022</year><volume>11</volume><fpage>1331</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1002/cpdd.1141</pub-id><pub-id pub-id-type="pmid">36045559</pub-id></element-citation></ref><ref id="B71-pharmaceutics-16-01044"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X.</given-names></name></person-group><article-title>A Three-Pulse Release Tablet for Amoxicillin: Preparation, Pharmacokinetic Study and Physiologically Based Pharmacokinetic Modeling</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0160260</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0160260</pub-id><pub-id pub-id-type="pmid">27479702</pub-id><pub-id pub-id-type="pmcid">PMC4968835</pub-id></element-citation></ref><ref id="B72-pharmaceutics-16-01044"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adjei</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kollins</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>A.</given-names></name></person-group><article-title>A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR&#174;) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder</article-title><source>Paediatr. Drugs</source><year>2020</year><volume>22</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1007/s40272-020-00409-z</pub-id><pub-id pub-id-type="pmid">32776159</pub-id><pub-id pub-id-type="pmcid">PMC7529626</pub-id></element-citation></ref><ref id="B73-pharmaceutics-16-01044"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woillard</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Debord</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name></person-group><article-title>Comment on &#8220;Population Pharmacokinetics of Mycophenolic Acid: An Update&#8221;</article-title><source>Clin. Pharmacokinet.</source><year>2018</year><volume>57</volume><fpage>1211</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1007/s40262-018-0687-9</pub-id><pub-id pub-id-type="pmid">29923171</pub-id></element-citation></ref><ref id="B74-pharmaceutics-16-01044"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoeckel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hengstmann</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Sch&#252;ttler</surname><given-names>J.</given-names></name></person-group><article-title>Pharmacokinetics of Fentanyl as a Possible Explanation for Recurrence of Respiratory Depression</article-title><source>Br. J. Anaesth.</source><year>1979</year><volume>51</volume><fpage>741</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1093/bja/51.8.741</pub-id><pub-id pub-id-type="pmid">497071</pub-id></element-citation></ref><ref id="B75-pharmaceutics-16-01044"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estebe</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Le Corre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Levron</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Le Moing</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Le Naoures</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ecoffey</surname><given-names>C.</given-names></name></person-group><article-title>Pilot Study on the Effect of Tourniquet Use on Sufentanil Pharmacokinetics</article-title><source>J. Clin. Anesth.</source><year>2002</year><volume>14</volume><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/S0952-8180(02)00458-0</pub-id><pub-id pub-id-type="pmid">12565115</pub-id></element-citation></ref><ref id="B76-pharmaceutics-16-01044"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cockshott</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Briggs</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>White</surname><given-names>M.</given-names></name></person-group><article-title>Pharmacokinetics of Propofol in Female Patients. Studies Using Single Bolus Injections</article-title><source>Br. J. Anaesth.</source><year>1987</year><volume>59</volume><fpage>1103</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1093/bja/59.9.1103</pub-id><pub-id pub-id-type="pmid">3499160</pub-id></element-citation></ref><ref id="B77-pharmaceutics-16-01044"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levron</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Trang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vaxelaire</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Flaisler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vourc&#8217;h</surname><given-names>G.</given-names></name></person-group><article-title>Pharmacokinetics of Phenoperidine in Anaesthetized Patients Undergoing General Surgery</article-title><source>Br. J. Anaesth.</source><year>1985</year><volume>57</volume><fpage>872</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1093/bja/57.9.872</pub-id><pub-id pub-id-type="pmid">4027103</pub-id></element-citation></ref><ref id="B78-pharmaceutics-16-01044"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherwin</surname><given-names>C.M.T.</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Goebel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vinks</surname><given-names>A.A.</given-names></name></person-group><article-title>The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease</article-title><source>Clin. Pharmacokinet.</source><year>2011</year><volume>50</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.2165/11536640-000000000-00000</pub-id><pub-id pub-id-type="pmid">21142265</pub-id><pub-id pub-id-type="pmcid">PMC5565486</pub-id></element-citation></ref><ref id="B79-pharmaceutics-16-01044"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Landersdorfer</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Paik</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Myung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Horkovics-Kovats</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bulitta</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>B.S.</given-names></name></person-group><article-title>Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans</article-title><source>AAPS J.</source><year>2015</year><volume>17</volume><fpage>1210</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1208/s12248-015-9764-2</pub-id><pub-id pub-id-type="pmid">25990964</pub-id><pub-id pub-id-type="pmcid">PMC4540730</pub-id></element-citation></ref><ref id="B80-pharmaceutics-16-01044"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koloskoff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Benito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chambon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dayan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marquet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jacqz-Aigrain</surname><given-names>E.</given-names></name><name name-style="western"><surname>Woillard</surname><given-names>J.-B.</given-names></name></person-group><article-title>Limited Sampling Strategy and Population Pharmacokinetic Model of Mycophenolic Acid in Pediatric Patients with Systemic Lupus Erythematosus: Application of a Double Gamma Absorption Model with SAEM Algorithm</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2024</year><volume>80</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s00228-023-03587-0</pub-id><pub-id pub-id-type="pmid">37897528</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-16-01044-f001" orientation="portrait"><label>Figure 1</label><caption><p>(<bold>a</bold>) Kinetic processes present in the EHC. Additional kinetic processes may occur, such as fecal elimination of a fraction of the drug secreted in the bile or not absorbed, renal elimination, distribution to peripheral tissues, hepatic biotransformation, and release of the pharmaceutical form for drugs for extravascular administration; (<bold>b</bold>) scheme of the compartmental model implemented for the simulation of the EHC. Rectangles with rounded corners represent the model compartments. The yellow circles represent the drug transfer parameters between the compartments, the majority being first-order constants. Green ellipses represent drug transfer parameters that are defined by an equation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g001.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f002" orientation="portrait"><label>Figure 2</label><caption><p>Pharmacokinetic simulations at different percentages of drugs undergoing enterohepatic circulation. The plasma profile in the middle of the drug concentrations in the gallbladder and below the kinetics of gallbladder emptying are shown above, expressed as variation in the <italic toggle="yes">k<sub>gem</sub></italic> according to Equation (3).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g002.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f003" orientation="portrait"><label>Figure 3</label><caption><p>Effect of <italic toggle="yes">EHC</italic>% on cumulative AUC. On the (<bold>left</bold>), the temporal dynamics of the percentage of drugs subjected to <italic toggle="yes">EHC</italic>% is shown, and on the (<bold>right</bold>), the temporal increase in the cumulative <italic toggle="yes">AUC</italic> is shown.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g003.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f004" orientation="portrait"><label>Figure 4</label><caption><p>Fitting of empirical models to data from a representative simulated pharmacokinetic profile. In this figure, the adjustment was made to the data obtained through a meal-based sampling, where up to 80% of the drug undergoes EHC.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g004.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f005" orientation="portrait"><label>Figure 5</label><caption><p>Scatter plots of the accuracy of <italic toggle="yes">AUC</italic> versus <italic toggle="yes">AICc</italic> and <italic toggle="yes">R</italic><sup>2</sup> of each model (<italic toggle="yes">M</italic>0&#8211;<italic toggle="yes">M</italic>5).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g005.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f006" orientation="portrait"><label>Figure 6</label><caption><p>Accuracy of <italic toggle="yes">AUC</italic> predicted by model <italic toggle="yes">M</italic>5 and by the trapezoidal method for each pharmacokinetic scenario. Calculation was made from data obtained from a meal-based sampling.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g006.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f007" orientation="portrait"><label>Figure 7</label><caption><p>Fit of model <italic toggle="yes">M</italic>5 to drug profiles submitted to 40% (<bold>top</bold>), 60% (<bold>middle</bold>), and 80% (<bold>bottom</bold>) of <italic toggle="yes">EHC</italic>%. Data were adjusted using meal-based (Sampling I) and conventional (Sampling II) samplings, as shown in <xref rid="pharmaceutics-16-01044-t004" ref-type="table">Table 4</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g007.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f008" orientation="portrait"><label>Figure 8</label><caption><p>Fit of model <italic toggle="yes">M</italic>5 to drug profiles submitted to 40% (<bold>top</bold>), 60% (<bold>middle</bold>), and 80% (<bold>bottom</bold>) of <italic toggle="yes">EHC</italic>%. Adjustment to the data was performed by sampling for the TDM, as shown in <xref rid="pharmaceutics-16-01044-t004" ref-type="table">Table 4</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g008.jpg"/></fig><fig position="float" id="pharmaceutics-16-01044-f009" orientation="portrait"><label>Figure 9</label><caption><p>Comparison between reported for drugs that undergo EHC and <italic toggle="yes">AUC</italic> predicted by model <italic toggle="yes">M</italic>5.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-16-01044-g009.jpg"/></fig><table-wrap position="float" id="pharmaceutics-16-01044-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t004_Table 4</object-id><label>Table 4</label><caption><p>Sampling schemes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sampling Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sampling Times (h)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Samples</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Meal-based sampling</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0, 0.5, 1, 2, 3, 4, 5, 6, 10, 11, 12, 16, 17, 18, 29, 53, 77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Focuses on sampling before and after food intake</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Conventional sampling</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 7, 9, 12, 24, 48, 72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prioritize sampling at the beginning to characterize <inline-formula><mml:math id="mm296" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula><inline-formula><mml:math id="mm297" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mi>and</mml:mi><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>
</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sampling for TDM</td><td align="center" valign="middle" rowspan="1" colspan="1">TDM1</td><td align="center" valign="middle" rowspan="1" colspan="1">0, 1, 3, 4, 6</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduce the number of samples and restrict their taking to the first hours after administration</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDM2</td><td align="center" valign="middle" rowspan="1" colspan="1">0, 1, 3, 4, 6, 10</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDM3</td><td align="center" valign="middle" rowspan="1" colspan="1">0, 1, 3, 4, 6, 10, 12</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDM4</td><td align="center" valign="middle" rowspan="1" colspan="1">0, 1, 3, 4, 6, 10, 12, 16</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDM5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0, 1, 3, 4, 6, 10, 12, 16, 18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-16-01044-t005" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t005_Table 5</object-id><label>Table 5</label><caption><p>Average <inline-formula><mml:math id="mm298" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mo>&#8734;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> per scenario.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
Scenario
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula id="FD18-pharmaceutics-16-01044">
<mml:math id="mm299" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mi mathvariant="bold-italic">U</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="bold-italic">&#8734;</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:math>
</inline-formula>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Scenario</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula id="FD19-pharmaceutics-16-01044">
<mml:math id="mm300" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mi mathvariant="bold-italic">U</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="bold-italic">&#8734;</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:math>
</inline-formula>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Scenario</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula id="FD20-pharmaceutics-16-01044">
<mml:math id="mm301" overflow="scroll"><mml:mrow><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mi mathvariant="bold-italic">U</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="bold-italic">&#8734;</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm585" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>&#160;<sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">26.45 &#177; 2.73</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm586" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>7</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">23.91 &#177; 3.24</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm587" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">23.77 &#177; 3.31</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm588" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>&#160;<sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">16.51 &#177; 3.86</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm589" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">23.86 &#177; 3.25</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm590" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>14</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">24.10 &#177; 3.13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm591" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>&#160;<sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4.89 &#177; 0.64</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm592" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>9</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">23.89 &#177; 3.24</td><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm593" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>&#160;<sup>a,b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">9.74 &#177; 4.34</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm594" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>&#160;<sup>a,b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">87.52 &#177; 9.84</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm595" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">23.89 &#177; 3.23</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm596" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>16</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">20.54 &#177; 4.54</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><inline-formula><mml:math id="mm597" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>&#160;<sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">12.86 &#177; 3.56</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm598" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">24.07 &#177; 3.15</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm599" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>17</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" rowspan="1" colspan="1">23.49 &#177; 3.38</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm500" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mn>6</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>&#160;<sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.06 &#177; 2.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm501" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.38 &#177; 3.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm302" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mn>18</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</inline-formula>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.64 &#177; 3.25</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Due to the greater persistence of drugs in the organism, simulation time was longer than 96 h in these scenarios. <sup>b</sup> Scenarios with <italic toggle="yes">p</italic>-values less than 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-16-01044-t006" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t006_Table 6</object-id><label>Table 6</label><caption><p>Means of the criteria for model selection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm502" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold">Adjusted</mml:mi><mml:mtext>&#160;</mml:mtext><mml:msup><mml:mi mathvariant="bold-italic">R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:math>
</inline-formula>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm303" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:mstyle></mml:mrow></mml:math>
</inline-formula>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Accuracy (%)&#160;<inline-formula><mml:math id="mm304" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mi mathvariant="bold-italic">U</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="bold-italic">&#8734;</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:math></inline-formula>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>0</td><td align="center" valign="middle" rowspan="1" colspan="1">0.827 &#177; 0.14</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;51.9 &#177; 12.3</td><td align="center" valign="middle" rowspan="1" colspan="1">88.4 &#177; 18.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.940 &#177; 0.17</td><td align="center" valign="middle" rowspan="1" colspan="1">150.4 &#177; 12.6</td><td align="center" valign="middle" rowspan="1" colspan="1">75.9 &#177; 13.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.888 &#177; 0.26</td><td align="center" valign="middle" rowspan="1" colspan="1">52.1 &#177; 31.8</td><td align="center" valign="middle" rowspan="1" colspan="1">89.6 &#177; 17.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.931 &#177; 0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">63.3 &#177; 25.8</td><td align="center" valign="middle" rowspan="1" colspan="1">84.2 &#177; 14.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.943 &#177; 0.12</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;51.1 &#177; 19.1</td><td align="center" valign="middle" rowspan="1" colspan="1">86.4 &#177; 16.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M</italic>5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.979 &#177; 0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;58.1 &#177; 14.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105.9 &#177; 21.4</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-16-01044-t007" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t007_Table 7</object-id><label>Table 7</label><caption><p>Results of NLR and <italic toggle="yes">AUC</italic> estimation of representative drugs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of<break/>Samples</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of<break/>Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Accuracy (%)<break/>
<inline-formula><mml:math id="mm305" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mi mathvariant="bold-italic">U</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi mathvariant="bold-italic">&#8734;</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:math></inline-formula>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<inline-formula>
<mml:math id="mm306" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold">Adjusted</mml:mi><mml:mtext>&#160;</mml:mtext><mml:msup><mml:mi mathvariant="bold-italic">R</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mstyle></mml:mrow></mml:math>
</inline-formula>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><inline-formula><mml:math id="mm307" overflow="scroll"><mml:mrow><mml:mstyle mathvariant="bold"><mml:mrow><mml:mi mathvariant="bold">Half</mml:mi><mml:mtext>-</mml:mtext><mml:mi mathvariant="bold">Life</mml:mi><mml:mtext>&#160;</mml:mtext><mml:msub><mml:mi mathvariant="bold-italic">t</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:math></inline-formula><break/>(h)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Meloxicam</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">124.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8013</td><td align="center" valign="middle" rowspan="1" colspan="1">39.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B44-pharmaceutics-16-01044" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sorafenib</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">110.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8791</td><td align="center" valign="middle" rowspan="1" colspan="1">25.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B45-pharmaceutics-16-01044" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Amiodarone</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">117.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9689</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B46-pharmaceutics-16-01044" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Methotrexate</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">95.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9684</td><td align="center" valign="middle" rowspan="1" colspan="1">5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B47-pharmaceutics-16-01044" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cyclosporin</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">93.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9494</td><td align="center" valign="middle" rowspan="1" colspan="1">8.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B48-pharmaceutics-16-01044" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Isotretinoin</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">104.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9591</td><td align="center" valign="middle" rowspan="1" colspan="1">23.5</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B49-pharmaceutics-16-01044" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Febuxostat</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">102.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9652</td><td align="center" valign="middle" rowspan="1" colspan="1">2.78</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B50-pharmaceutics-16-01044" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Toremifene</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">104.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9912</td><td align="center" valign="middle" rowspan="1" colspan="1">29.7</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B51-pharmaceutics-16-01044" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Atorvastatin</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">98.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9400</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B52-pharmaceutics-16-01044" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ezetimibe</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">78.4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8524</td><td align="center" valign="middle" rowspan="1" colspan="1">15.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B53-pharmaceutics-16-01044" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ezetimibe</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">84.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8586</td><td align="center" valign="middle" rowspan="1" colspan="1">13.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B53-pharmaceutics-16-01044" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Indomethacin</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">92.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9736</td><td align="center" valign="middle" rowspan="1" colspan="1">6.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B54-pharmaceutics-16-01044" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Genistein</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">95.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9527</td><td align="center" valign="middle" rowspan="1" colspan="1">4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B55-pharmaceutics-16-01044" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fimasartan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7552</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-pharmaceutics-16-01044" ref-type="bibr">56</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> The elimination half-life of amiodarone is biphasic; the half-life of the first phase of disposition is presented here since the actual half-life is between 25 and 110 days.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-16-01044-t008" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-16-01044-t008_Table 8</object-id><label>Table 8</label><caption><p>Number of parameters required to characterize a plasma profile.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Model</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Minimum Number of Parameters and Samples per Peak <sup>a</sup></th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>1</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>2</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>3</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">M</italic>4</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">M</italic>5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> Refers to the minimum number of parameters required by each model to characterize 1, 2, 3, and 4 peaks of the plasma profile.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>